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ABSTRACT OF DISSERTATION

APOE GENOTYPE AND CEREBRAL GLUCOSE METABOLISM: A MULTI-OMICS
APPROACH
Apolipoprotein E (APOE) is encoded by the APOE gene, present in humans as
three main isoforms (E2, E3, and E4). E4 carriers face up to a 15-fold increased risk for
developing late-onset Alzheimer’s disease (AD), while E2 carriers are protected.
Understanding the risk conferred by E4 has been an extensive research focus for nearly
three decades, but the exact mechanism has yet to be proven. Many studies have
demonstrated attenuated roles of E4 in classical hallmarks of AD, notably amyloid
processing and neurofibrillary formation, which normally present later in disease
progression. How APOE influences hallmarks that present much earlier are not as wellcharacterized and may indicate how E4 confers greater risk with an earlier age of disease
onset. One such hallmark of AD is cerebral glucose hypometabolism, which happens to
also be present in young cognitively normal E4 carriers. The specific cell types responsible
for this reduction are unknown; however, an important role of astrocytes, which are the
main producers of APOE in the brain, is to facilitate glucose uptake from the vasculature
to provide metabolic support for neurons. Therefore, I hypothesize astrocytes are primarily
responsible for the reduction in cerebral glucose uptake associated with E4, specifically
due to impairments in glucose metabolism. In vivo brain metabolism in human APOE mice
(E2, E3, or E4) was examined using an oral gavage of [U-13C] glucose. Glucose
metabolism in immortalized astrocytes expressing human APOE E2, E3, or E4 was
measured using stable isotope resolved metabolomics via a [U-13C] glucose tracer
supplemented growth media. Cell culture and brain metabolite profiles were analyzed
using mass spectrometry to determine glucose utilization by tracing the enrichment of 13C
atoms in central carbon metabolism pathways. Lastly, a combined multi-omics approach
was utilized to determine the metabolic and transcriptomic changes associated with
inflammation in astrocytes. Immortalized astrocytes (E3 and E4) were subjected to an acute
inflammatory challenge consisting of pro-inflammatory mediators (TNFα, IL-1α, and
C1q). Metabolic phenotyping of E3 and E4 astrocytes was conducted by Seahorse
mitochondrial and glycolytic rate assays, steady state metabolomics, and further examined
using stable isotope resolved metabolomics with a [U-13C] glucose tracer in primary mixed
glial cultures. Transcriptional changes in E3 and E4 astrocytes after inflammatory
challenge were determined using Nanostring neuroinflammatory gene expression arrays.
E4 mice exhibited alterations in glucose flux through central carbon metabolism,
specifically in glycolysis and the TCA cycle. In vitro findings revealed E4 astrocytes
redirected glucose flux through glycolysis into the non-oxidative pentose phosphate
pathway. Glutathione, phospholipid species, NADH, and nucleotide biosynthesis from

glucose was also increased in E4 astrocytes, suggesting an inflammatory or oxidative stress
component. Following acute inflammatory stimulation, E4 astrocytes exhibited altered
glycolytic function, disrupted metabolic responses, and blunted inflammatory gene
expression compared to E3 astrocytes. These findings begin to shed light on the cell type
specific effects of APOE by which immunometabolism, especially in E4 carriers, may lead
to progression of AD and may direct future development of therapeutics.
KEYWORDS: APOE, glucose metabolism, astrocyte, neuroinflammation, reactive
astrocytes
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CHAPTER 1. THE INFLUENCE OF APOE ON ALZHEIMER’S DISEASE
1.1

Alzheimer’s disease
As the leading cause of dementia worldwide, late-onset Alzheimer’s disease (AD)

affects an estimated 40 million people globally as of 2018, with more than six million
Americans currently diagnosed with AD [1, 2]. After the age of 65 the risk for developing
AD doubles every five years, and with a substantial rise in the aging population, the
prevalence of AD is expected to triple in number within 30 years [3]. Clinical diagnostic
criteria for AD include symptoms of cognitive decline with progressive worsening in
conjunction with histopathological evidence of senile plaques and neurofibrillary tangles,
which can only be obtained upon autopsy or brain biopsy. Considering the inherent risks
associated with a brain biopsy, most AD patients are considered “probable” cases, only to
be confirmed as “definitive” post-mortem [4]. Unfortunately, a confirmed AD diagnosis
is costly and the current treatment options available do not delay progression, which
underscores the importance of research as further understanding of risk factors and
potential causes may lead to the development of better treatment options [5]. In this
chapter, I will discuss the various features of AD and its known risk factors, with special
emphasis on the genetic risk factor Apolipoprotein E (APOE) and cerebral metabolism.
The classical pathological hallmarks of AD include senile plaques, the result of
extracellular beta-amyloid (Aβ) deposition, and neurofibrillary tangles, comprised of
intracellular highly phosphorylated tau. Apart from amyloid and tau protein aggregates,
other hallmarks of AD include neuroinflammation, neuronal cell loss, cortical thinning,
and glucose hypometabolism [4]. Certain features of AD present prior to the onset of
clinical symptoms. This includes: Aβ and tau, detected in cerebrospinal fluid (CSF) or via
1

positron emission topography (PET) scans; topology features of glucose hypometabolism,
defined as a reduction in cerebral glucose uptake measured using 18FDG-PET; and cortical
changes in connectivity measured through functional MRI scans [6-8]. Although the exact
biological mechanism of disease onset is unknown, current data-driven hypotheses point
toward a concomitant cause from many biological features acting over time which
ultimately manifest in clinical symptoms.
AD affects higher cognitive function including but not limited to learning and
memory, executive function, social cognition, episodic memory, and language—that
eventually lead to disruption of daily tasks. These cognitive defects ultimately require
extensive patient care, the cost of which has a considerable impact on society; however,
the impact on the family members involved is insurmountable in comparison. The
financial burden of care costs billions of dollars per year and is only increasing as the aging
population grows, while the emotional impact of the disease overshadows the financial
burden as patients lose memory of loved ones and their care often falls on these family
members [2].
While AD is widely known as a disease of aging, the disease can also present earlier
in life. Early-onset Alzheimer’s disease (EOAD) is distinguishable from AD by the age at
which disease onset occurs and accounts for an estimated 5-10% of total cases worldwide
[9, 10]. EOAD is most often characterized by an onset prior to 65 years of age and is
commonly referred to as familial AD due to an autosomal dominant inheritance pattern of
mutations in three genes associated with normal amyloid processing. Specifically,
mutations in genes encoding for presenilin (PSEN1, PSEN2) or amyloid precursor protein
(APP) affect the synthesis and proteolysis of amyloid, leading to an accumulation of
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pathogenic levels that ultimately result in early disease onset and rapid progression.
However, recent studies suggest familial AD accounts for a much smaller portion of
EOAD cases (10% or less) than previously thought [9, 11, 12]. The emerging evidence
shows the majority of EOAD cases were not attributable to a pattern of autosomal
dominant inheritance, hence they are classified as non-mendelian EOAD [9, 11, 12]. The
lack of a clear inheritance pattern, largely unknown genetic etiology, and widely variable
age of onset offer poor predictability of non-mendelian EOAD occurrences [11].
Fortunately, the vast majority of all AD cases—which occur later in life—can be predicted
with much more precision due to a greater understanding of the risk factors associated with
[late-onset] AD.
In addition to nearly 30 known genetic risk factors, several environmental factors
also influence overall risk of AD [11]. Education, social engagement, and physical activity
throughout life reduce the risk for developing dementia later in life, while depression and
patterns of poor sleep—such as those occurring with insomnia and sleep apnea—are
associated with cognitive decline and increased AD risk [13-16]. Traumatic brain injury
or other physical insult to the CNS increases inflammation whereby contributing to the
development of AD [17]. The majority of genetic risk factors identified for AD exert a
relatively small effect on overall risk and offer little clinical significance; while,
conversely, a handful of genes exhibit larger effects on disease risk, including certain
variants of TREM2, APP, and PSEN1/2—but are quite rare in the population [18-21].
However, unlike most genetic risk factors for AD, the ε4 allele of APOE is neither rare nor
a miniscule risk, and thus poses promising clinical significance.

3

1.2

Apolipoprotein E in the population and its role in lipid transport
The strongest genetic risk factor associated with late-onset AD is APOE genotype.

The APOE gene encodes for apolipoprotein E (APOE), which has three main isoforms in
humans (E2, E3, and E4). Presence of the ε4 allele is the greatest predictor for AD other
than age, conferring up to a 15-fold higher risk in homozygous carriers (ε4/ε4) with the
overall odds of any ε4 carrier developing disease being 3.68 times greater than ε3/ε3
carriers [22]. Conversely, ε2 is protective against AD, reducing risk by up to 40%, but
unfortunately is quite rare in the population with less than 7% of people globally carrying
at least one copy [23, 24]. The ε3 allele, regarded as neutral in risk, is the most prevalent
isoform present in roughly 79% of the population. While the prevalence of ε4 is only 14%
globally, nearly half (48.7%) of all AD cases are carriers of at least one ε4 allele [25].
Despite nearly three decades of research after the initial discovery of APOE as a risk factor
for AD, the biological mechanism behind the wide range of risk, whether positive or
negative, is still unclear—yet results from only three single nucleotide polymorphisms in
the APOE gene.
On chromosome 19, nearly 3,600 base pairs encode the APOE gene, consisting of
three introns and four exons that ultimately result in transcription of an APOE protein 299
amino acids in length [26]. The E2, E3, and E4 isoforms are attributed to single nucleotide
polymorphisms that alter amino acid residues either at position 112 or 158. The more
prevalent E3 isoform contains a cysteine at position 112 and an arginine at position 158,
the conformation of E2 contains cysteine residues at both positions, whereas two arginine
residues result in the E4 isoform [27].
APOE is expressed in various tissues throughout the body but is most highly
expressed by hepatocytes in the liver. While astrocytes are known as the predominate
4

source of APOE in the central nervous system, APOE expression is not ubiquitous across
all astrocytes nor is it restricted to only astrocytes. Fluorescent-tagged mouse APOE
revealed roughly 25% of astrocytes did not express any APOE, while expression among
other cell types was conditional [28]. Microglia express APOE in relatively low quantities
compared to astrocytes and increase production in disease states or during activation [28,
29]. APOE synthesis in neurons is regulated by astrocytes and absent under normal
conditions but drastically upregulated after injury [28, 30, 31].
Although APOE is a pleiotropic protein, the canonical role in both the periphery
and brain is trafficking lipids and assisting in cholesterol efflux from cells. It was first
identified as a constituent of very low-density lipoproteins (VLDL), and later discovered
to also be associated with high-density lipoproteins (HDL) and chylomicron remnants [3234]. APOE promotes internalization of lipoproteins through binding with receptors in the
low-density lipoprotein (LDL) receptor family [33]. In the brain, APOE binds with several
members of the LDL receptor family including: Apoer2 and VLDLR, which play roles in
neural signaling and tau phosphorylation; LDLR and LRP1, which regulate APOE levels
in the brain [35-37]. However, the efficacy of receptor binding often occurs in an isoformdependent manner. For example, E4 binds to LDLR with an affinity slightly greater than
E3, while E3 and E4 bind with much higher affinity than E2 [38].
Differences in receptor binding are likely the result of structural differences among
the three isoforms. There are two structural components of APOE conserved across all
three major isoforms: the receptor binding (N-terminal) domain and the lipid binding (Cterminal) domain. The receptor binding domain is laden with arginine and lysine residues
which are involved in docking APOE to its receptors [39]. The E3 and E4 isoforms contain
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an arginine residue at position 158, which is outside the receptor binding domain but
indirectly assists in receptor binding, while E2 contains cysteine at position 158 that is
thought to interfere with the conformation of the domain and believed to contribute to the
type III hyperlipidemia that presents in approximately 10% of ε2/ε2 homozygotes [39, 40].
Lipoprotein affinity and lipid binding are also isoform-dependent. E2 and E3
isoforms are more commonly associated with HDL particles, while E4 shows preference
for the larger VLDL particles [41, 42]. Further, lipoproteins from E4 primary astrocytes
are less lipidated compared to that of E2 or E3 astrocytes [43]. However, despite the poor
lipidation of E4, human iPSC-derived astrocytes expressing E4 secrete more cholesterol
than E3 and surprisingly show higher intracellular cholesterol [44]. These differences in
lipid binding are attributed to the arginine residue at position 112, specific to the E4
isoform, which forms a salt bridge with a nearby glutamate residue that allows for a second
salt bridge within the lipid binding domain, thus rearranging the conformation and thereby
enhancing the affinity for VLDL [39].
While structural differences among E2, E3, and E4 offer a mechanistic explanation
to the isoform-specific effects of APOE on lipid metabolism, it has fallen short in
providing a unifying mechanism that fully explains the entirety of risk for AD associated
with E4 carriers. As such, efforts to further understand how E4 imparts a greater risk for
AD have uncovered many additional disease-relevant alterations among APOE isoforms.

1.3

The effect of APOE in the brain – implications for Alzheimer’s disease
Despite nearly three decades of research since the discovery of APOE as a risk

factor for AD, a single disease-causing biological mechanism has yet to be fully elucidated.
Rather, a variety of different pathophysiological effects have been attributed to E4
6

carriage. For example, memory loss and cognitive decline are perhaps the most widely
known features of AD and are affected by APOE status. AD patients who are ε4 carriers
tend to show more memory loss compared to non-carriers, who are more likely to show
impairments in executive function, spatial processing, and language [45]. Several studies
of AD patients have concluded ε4 carriers showed faster rates of cognitive decline,
indicative of accelerated disease progression; however, other studies showed there was no
association based on APOE status, while a few have even reported ε4 was associated with
a slower rate of cognitive decline [45]. Whether disease progression is affected by APOE
genotype, though collectively is unclear, may depend on demographics or otherwise
restricted to certain subsets of AD patients based on sex or ancestry, and certainly age.
In addition to the overall increased risk for AD, ε4 carriers also face an earlier onset
of disease. The age of onset for ε4 carriers decreases roughly eight years per copy, with an
average onset at 68 years for homozygotes [46]. Age is a critical factor when determining
the effects of APOE on disease progression as studies conducted prior to AD diagnoses
revealed a higher prevalence of conversion from mild cognitive impairment to AD in ε4
carriers relative to non-carriers [47-49]. The influence of APOE also extends beyond the
clinical presentations of AD, extensively affecting myriad processes of the pathobiology.
During the progression of AD, patients develop brain atrophy, or cortical thinning,
defined as a volumetric reduction in brain volume [50]. The pattern of brain atrophy in AD
patients is dependent upon APOE genotype. Typically, brain atrophy due to AD begins in
the temporal lobe, progresses to the parietal lobe, and then reaches the frontal lobe in later
stages of disease [51]. AD patients with ε4 show a greater extent of cortical thinning in the
temporal lobe, specifically the amygdala, entorhinal cortex, and hippocampus.
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Alternatively, non-carriers with AD show a greater loss of volume in the parietal and
frontal lobes compared to ε4 carriers [45]. These regional-specific differences in brain
atrophy interestingly correlated with differences in cognition, respective of APOE
genotype. Patients who were memory-impaired displayed a greater extent of brain volume
loss in the hippocampus and were more likely to be ε4 carriers, while patients showing
visuospatial and especially language impairments showed a greater loss of volume in
temporal and parietal regions and were more likely to be non-carriers [52, 53].
Differences in hippocampal degeneration based on APOE status could be attributed
to alterations in synaptic function and the ability to generate new neurons to compensate
for the neuronal loss resulting from disease processes. Evidence of APOE-dependent
effects on synaptic plasticity in humans have been demonstrated through functional MRI
in young ε4 carriers, which revealed alterations in functional connectivity that were similar
to those observed in AD patients [54]. Dystrophic neuronal projections are a pathological
feature of AD that are more prevalent in ε4-positive AD patients and mice expressing
human E4, which showed lower dendritic spine density and fewer arborizations [55, 56].
Additionally, AD patients with at least one ε4 allele showed reduced post-synaptic protein
levels, indicating a loss of synaptic function relative to non-carriers [57]. Further, animal
studies revealed E4 impaired neurogenesis in the hippocampus of adult mice which was
also corroborated in vitro [58, 59]. Several studies across a variety of neuronal cultures,
including studies that utilized astrocyte-derived APOE, have demonstrated stimulatory
effects of E3 on neuritogenesis and conversely shown inhibitory effects of E4 [60-62].
Additionally, this process may be influenced by APOE receptors APOER2 and
VLDLR, which play a role in neurogenesis and synaptic function. In primary cortical
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neurons from mice expressing human APOE isoforms, E4 neurons, relative to E2 or E3,
had reduced Apoer2 surface expression that decreased Reelin signaling, a protein which
also binds Apoer2 and regulates neuronal migration and synaptic plasticity [63, 64].
Additionally, Reelin-dependent long-term potentiation was also inhibited in the
hippocampus of E4 mice when compared to E2 or E3, which is a process important for
protection from Aβ toxicity [63, 65].
Further effects of APOE on Aβ have been described in animal models of disease.
Studies in E4FAD mice (human E4 targeted-replacement with Aβ overexpression) have
shown that APOE binds Aβ directly and that the E4 isoform increases Aβ accumulation
and impairs clearance [35, 66, 67]. While the more specific effects of APOE on amyloid
and tau pathology have been extensively investigated in cell culture systems and animal
models of disease, the most compelling results are from humans. Post-mortem studies of
AD patients have demonstrated ε4 carriers displayed increased Aβ deposition occurring in
an ε4 dose-dependent manner and similar results were also reported in younger, nondemented adults, where ε4 carriers showed more Aβ deposition than non-carriers starting
at 30 years of age [68-72]. Post-mortem studies examining tau pathology in AD patients
have reported greater tau burden among ε4 carriers in gene dose-dependent manner [7375].
Interestingly, a greater extent of vascular Aβ deposition and tau pathology
surrounding the vasculature has been described in ε4/ε4 AD patients [76]. Furthermore,
AD patients with at least one copy of ε4 showed disruptions in cerebral blood flow and
decreased blood brain barrier (BBB) integrity relative to non-carriers [77, 78].
Cerebrovascular impairments appear to be more a feature of ε4 than they are a result of
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AD pathology as younger ε4 carriers show cerebrovascular dysfunction even when
cognitively normal. In concert with cerebrovascular dysfunction observed in E4FAD mice,
the overall impact of AD due to ε4 is likely worsened by vascular impairments, which may
shed light as to the correlation between AD and vascular dementia—a common
comorbidity of AD, especially among ε4 carriers [79].
Other diseases more common in ε4 carriers include multiple sclerosis, cardiovascular
disease, and type II diabetes, some of which are comorbidities of AD [80, 81]. Type II
diabetes is a major comorbidity of AD, particularly in ε4 carriers as the effects of which
are synergistic with the presence of ε4. Individuals with diabetes and who carry an ε4 allele
face a five-fold greater risk for AD than ε4 carriers without diabetes [82]. Given the
increased risk among ε4 carriers for developing these diseases, which all have a strong
inflammatory and, in most cases, a metabolic component, and considering the recent shift
in focus for AD researchers toward investigating a more inflammation-driven disease
progression, it is important to determine whether an underlying inflammatory deficit
associated with ε4 is contributing to the higher prevalence of AD.

1.4

Neuroinflammation and Alzheimer’s disease – effects of APOE
In AD, neuroinflammation predates senile plaque formation and is a significant

pathogenic mediator of amyloid deposition, tau accumulation, blood-brain barrier
permeability, and synaptic dysfunction [83, 84]. Although neuroinflammation and APOE
will be discussed in greater detail in Chapter 4, it is important to briefly introduce the
concept of neuroinflammation and discuss its implications on AD [83, 85].
The neuroinflammatory response is a coordinated multicellular reactionary process
of the CNS in response to noxious stimuli that is primarily initiated through molecular
10

exchanges between astrocytes and microglia. These dynamic interactions induce
functional and morphological changes in both cell types that are now recognized as
differences in “activation” state. After a CNS insult, microglia switch from a homeostatic
resting state to an activated state as part of the innate immune response, although the
specific response, whether pro- or anti-inflammatory, depends on the nature of the insult
[86, 87].
The neuroinflammatory response in vivo differs based on APOE status, reflected by
several studies in humans and animal models that generally show that E4 is associated
with an exaggerated pro-inflammatory response [88]. For example, post-mortem studies
in humans have shown more activated microglia and astrocyte reactivity in E4 carriers,
while E2 carriers showed higher levels of homeostatic microglia [89]. After inflammatory
stimulation via intraperitoneal injection of lipopolysaccharide (LPS) in human APOE
mice, E4 mice showed a more profound neuroinflammatory response relative to E2 or E3
mice, indicated by increased microglial activation and prolonged pro-inflammatory
cytokine levels [90]. It is known microglia upregulate production and secretion of proinflammatory mediators in the presence of Aβ. However, given microglial activation and
astrocyte reactivity often precede AD pathological hallmarks of Aβ deposition and tau
tangle formation, the exact mechanism of glial activation prior to disease onset is unclear,
but appears to be APOE-dependent [91, 92].
In a neurodegenerative disease setting such as AD, activated microglia secrete proinflammatory mediators that when taken up by astrocytes, induce a state of astrocyte
reactivity [92]. Interestingly, activated microglia isolated from E4 mice showed increased
secretion of pro-inflammatory cytokines, including TNFα, a known mediator of astrocyte
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reactivity [93]. TNFα, Il-1α, and C1q were recently defined as the three primary microglial
specific mediators of astrocyte reactivity; however, other factors known to induce
astrocyte reactivity include toll-like receptor agonists, such as LPS; neurotransmitters
(glutamate and norepinephrine); ATP and other nucleotides; reactive oxygen species
(ROS); hypoxia and hypoglycemia; protein aggregates (Aβ and tau); ammonia toxicity
(NH4); and certain growth factors (FGF2 and endothelin-1) [94, 95].
Astrocyte reactivity was canonically defined as a change in morphology
characterized by increased glial-fibrillary acidic protein (GFAP) expression [96, 97].
However, this classification of reactive astrocytes has been expanded to encompass the
specific functional and molecular changes that differentiated them from normal astrocytes
[91]. The morphological changes in reactive astrocytes are attributed to increased
expression of intermediate filament proteins GFAP, vimentin, nestin, and synemin [98].
Functional changes in reactive astrocytes include pro-inflammatory chemokine release,
attenuated neurotrophic function, impaired phagocytic capacity, and a reduced capacity
for synaptic formation in neurons [95]. These functional changes are reflected by
alterations in genes involved in neuronal development, chemokine production
(predominately CXCL family), cytokine receptors, and phagocytic receptors [99]. Other
transcriptional alterations include genes involved in cell cycle/apoptosis, oxidative stress
response, extracellular matrix proteins, and immune response [99]. Specifically, genes
commonly used as markers of astrocyte reactivity are Lcn2, Gfap, Vimentin, and Timp1
[100].
The impact of reactive astrocytes in the brain is multifactorial, affecting synapse
formation and plasticity, neurotransmitter cycling, cation regulation (K+ and Ca2+), and
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BBB permeability. However, the effects of astrocyte reactivity on cerebral metabolism are
not as well characterized, as the vast majority of research on metabolism in the context of
neuroinflammation has been focused on microglia [101]. Although a handful of studies
have described metabolic changes in astrocytes in the context of neuroinflammation, the
field has yet to establish a consensus on how metabolism changes in reactive astrocytes
[98, 101, 102]. Furthermore, whether there are APOE isoform-specific effects is largely
unexplored. This knowledge gap in the field is addressed in Chapter 4.

1.5

Brain metabolism and the role of astrocytes
Glucose is the primary energy source in the brain, which consumes roughly 25% of

total body glucose [103]. Additionally, 20% of total body oxygen is also consumed by the
brain as it is required to sustain aerobic glycolysis – the predominate metabolic pathway
in the brain [103]. Maintaining normal brain function requires multiple energy-demanding
processes, which heavily rely upon astrocyte metabolism. Astrocytes sustain proper
neuronal function and survival by supplying neurons with metabolic products, many of
which are synthesized from glucose.
Astrocytes transport much of the glucose destined for the brain, which traverses from
the blood into endothelial cells and subsequently to astrocytic end-feet by facilitated
diffusion via glucose transporters [104, 105]. GLUT1 is the primary glucose transporter
along the BBB and is responsible for both efflux of glucose from endothelial cells and
influx of glucose to astrocytes [106]. Expression of GLUT3, GLUT4, and SGLT1 (Na+glucose cotransporter) have also been reported in small cerebral blood vessels in rodents,
however, their exact contributions are unclear [106]. Although glucose can also enter the
brain through tight junctions among neighboring endothelial cells or diffusion across the
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basal lamina between astrocytic end-feet, evidence suggests the majority is transported by
astrocytes [104, 107]. Additionally, astrocytes take up and metabolize other energy
substrates, mainly fatty acids, glutamine, and glutamate; however, glucose accounts for
approximately 70% of the total carbon taken up by astrocytes [108, 109].
Once glucose enters astrocytes it is metabolized by hexokinase as the first step in
glycolysis that generates glucose-6-phosphate (G6P), which is either metabolized further
by central carbon metabolism pathways or incorporated into glycogen via glycogenesis.
G6P that is further metabolized can enter the pentose phosphate pathway (PPP) or
complete glycolysis thereby generating ATP in the multistep enzymatic conversion to
pyruvate. Once the molecule is converted to pyruvate, its fate is either to enter the TCA
cycle where it can yield maximal ATP production (per molecule of glucose) via oxidative
phosphorylation or be converted to lactate. However, accounting for less than 20% of ATP
expenditure in the brain, astrocytes require less energy than neurons to sustain
physiological function [110]. Therefore, most glucose taken up by astrocytes is not fully
oxidized and is instead converted to lactate for transport to neurons as part of the astrocyteneuronal lactate shuttle (ANLS) [110, 111].
Although it may appear counterproductive, the ANLS is energetically favorable for
both astrocytes and neurons. The conversion of glucose to lactate generates ATP, albeit
less than that obtained via TCA cycle oxidation, and reducing equivalents that fuel
astrocytic energy demands while still yielding energy substrate for neurons. In neurons,
lactate must first be converted to pyruvate before utilized for energy production, which is
not energetically favorable; however, pyruvate can then be metabolized in the TCA cycle
to fuel the electron transport chain (ETC) for oxidation phosphorylation resulting in a net
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gain of ATP that is 7-fold greater than that generated by glycolysis alone. While the ANLS
has yet to be empirically proven in vivo, the theory posits that astrocyte metabolism is
upregulated (specifically glycolysis) in response to neural activity to meet increased
metabolism demands with brain activation.
Conversely, evidence in vivo suggests it is neurons that increase glycolysis to provide
pyruvate in response to neural activity [112]. Further evidence in vivo exclaims the ANLS
lacks stochiometric balance as the CMRglc increased disproportionately relative to the
CMRO2, which is required for lactate oxidation. The increase in glucose oxidation in the
absence of oxygen consumption was explained by a release of lactate from the brain,
instead of its oxidation. Another key aspect of the ANLS is that neuronal glutamate taken
up by astrocytes triggers glycolysis to provide energy for glutamate uptake while also
providing energy substrate (lactate) to neurons [113]. However, several studies both in
vitro and in vivo have shown glutamate taken up by astrocytes is oxidized via the TCA
cycle thereby providing the energy to sustain glutamate uptake, without increasing
glycolysis [114]. Although the contributions of the ANLS may be unclear, astrocyteneuronal metabolic coupling does occur and is critical for proper cerebral function.
Despite astrocytes undergoing glycolysis to a much greater extent than neurons, who
rely mainly on oxidative phosphorylation, the TCA cycle in astrocytes is vitally important,
and especially critical for neurons [110]. In addition to utilizing the TCA cycle to meet
resident energy demands, astrocytes also generate reducing equivalents and precursors
(mainly amino acids) for use in biosynthesis processes and neurotransmitter
recycling/synthesis. Glutathione, the main antioxidant in the CNS, is synthesized using
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dipeptides derived from the TCA cycle in astrocytes and is essential for neuronal survival
due to its role in mitigating oxidative stress [115, 116].
Glutamate, in addition to being a constituent of glutathione, is the major excitatory
neurotransmitter in the brain, and γ-aminobutyric acid (GABA), the major inhibitory
neurotransmitter, are both synthesized through the TCA cycle in astrocytes. The
glutamate-glutamine cycle describes the neurotransmitter recycling process by which
glutamate from the synaptic cleft is taken up by astrocytes, converted to glutamine and
transported back to neurons, where it is then reconverted back to glutamate for repackaging
into synaptic vesicles. The conversion of glutamate to glutamine in astrocytes, which
consumes NH4, plays a two-fold secondary role as a compensatory mechanism protecting
against excitotoxicity and the metabolic fixation of nitrogen to mitigate ammonia toxicity
[117]. As the glutamate-glutamine cycle does not operate stoichiometrically, there is a
need for de novo glutamate synthesis in astrocytes, which requires contributions from the
TCA cycle to generate α-ketoglutarate and glycolysis for anaplerosis of pyruvate [118].
Many metabolic processes in astrocytes depend on the pentose phosphate pathway
(PPP) as it generates NADPH, which is a cofactor necessary in recycling glutathione for
redox management and facilitates anabolic reactions including synthesis of purines and
pyrimidines, fatty acids, and cholesterol. Additionally, the PPP is the main source of
ribose, the 5-carbon backbone used in de novo nucleotide biosynthesis [119].
In summary, the role of glucose metabolism in astrocytes encompasses far more than
a source of energy in the brain. Each branch of central carbon metabolism, which
constitutes the major pathways involved in glucose metabolism, serves an ancillary role in
maintaining proper neurological function in addition to providing energy. It is for this
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reason – the interconnectedness of metabolism in astrocytes and the role of astrocytes as
acentral hub of glucose utilization in the brain – that perturbations in their ability to
metabolize glucose can result in reduced viability and function of both astrocytes and
neurons.

1.6

APOE-specific contributions to metabolism in the AD brain
There are many metabolic abnormalities observed in AD that influence glucose

metabolism in astrocytes, including lipid dysregulation, hormonal imbalance, and glucose
hypometabolism. Interestingly, many of these metabolic deficits are more prevalent and
often more severe in E4 carriers, some of which present decades prior to onset of AD.
Decreased cognitive decline in E2 carriers was associated with cholesterol
metabolism in the brain, while E4 has shown an array of cholesterol dysregulation in
animal models and cell culture systems alike [88, 120]. Specifically, human iPSC-derived
astrocytes showed higher intracellular cholesterol accumulation and increased cholesterol
secretion relative to E3 astrocytes [88]. AD patients display reduced serum and CSF
cholesterol levels, and decreased membrane-bound cholesterol relative to controls, which
may be sequestered in intracellular lipid droplets [121]. Lipid droplet formation was first
reported by Alois Alzheimer’s original characterized of the disease [122]. Interestingly,
E4 astrocytes display increased lipid droplet accumulation, which can be exacerbated by
oxidative stress and mitochondrial dysfunction. Finally, cholesterol synthesis and lipid
metabolism in the brain is regulated by insulin, which also has direct effects on cerebral
glucose metabolism [123].
Although dysfunction in hormones other than insulin have been reported in AD
patients, such as hypothalamus-pituitary-adrenal axis disruption, the effects of insulin on
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metabolism in the brain are more direct and as such, have been studied in much greater
detail [124, 125]. Insulin is actively transported across the BBB, which is regulated by
astrocytes; however, it is also synthesized within the CNS by neurons and astrocytes.
Furthermore, insulin receptors are also expressed by neurons and astrocytes found in the
hippocampus, olfactory bulb, cerebellum, cortex, and the hypothalamus, a critical region
of metabolic control [126].
The effects of insulin on total glucose uptake in the normal brain are likely minute
as the majority of cerebral glucose uptake is controlled by the insulin independent GLUT1
transporter [127, 128]. Nevertheless, AD patients develop insulin resistance, which can
result in deficient metabolic function within astrocytes including reduced energy
expenditure and mitochondrial dysfunction [123]. Insulin resistance and E4 have been
shown to synergistically reduce cerebral glucose uptake in humanized APOE mice [129].
E3 and E4 mice showed lower GLUT4 expression in the brain compared to E2 mice, while
E4 had lower expression of GLUT3 and GLUT4 relative to E3 mice [130, 131]. Although
no differences were found in GLUT1 expression, it is hypothesized that post-translational
modification of GLUT1 differs by APOE genotype which may contribute to differences in
brain glucose uptake [131, 132].
Impaired glucose uptake is one of the earliest detectible features of AD and is also
strongly influenced by APOE status. Cerebral glucose hypometabolism, defined as a
reduction in glucose uptake that is indicated by decreased 18FDG-PET signal, occurs prior
to AD pathological hallmarks and cognitive decline [133-135]. Cerebral glucose
hypometabolism is also the strongest predictor of progression from MCI to AD and the
extent of which strongly correlates with severity of clinical symptoms—an observation
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that is perhaps more striking considering amyloid deposition shows a comparatively weak
correlation with severity of AD [136, 137]. The reduced cerebral metabolic rate of glucose
(CMRglc), determined by the rate of glucose uptake measured by 18FDG-PET, observed in
AD brains was independent of amyloid and tau pathologies and was not attributable to
brain atrophy or decreased brain activity [138].
The AD brain typically displays glucose hypometabolism in the temporal and
parietal lobes, posterior cingulate cortex, precuneus, and develops in the prefrontal cortex
during later stages of disease. Interestingly E4 carriers display a similar regional pattern of
reduction in glucose uptake, even in young, cognitively normal individuals [139, 140].
Oxidative damage is most prevalent in brain regions showing glucose hypometabolism
and especially elevated in the frontal cortex of AD patients, which correlated with the
presence of E4 [136, 141].
Oxidative stress is increased when reactive oxygen species (ROS) are generated in
excess by mitochondria, which can occur with increased oxidative phosphorylation. There
is a metabolic shift toward favoring oxidative phosphorylation associated with aging that
is proposed to occur sooner in E4 carriers, ultimately contributing to elevated oxidative
stress [88]. With increased reliance on mitochondria for ATP synthesis, deficits in
respiratory chain complexes can result in hypometabolism [142].
Post-mortem analysis of human brain tissue revealed evidence of mitochondrial
dysfunction at the transcriptional level in cognitively normal, young E4 carriers, evidenced
by decreased expression of genes involved in respiratory chain complexes [143]. These
findings are also supported by in vivo results showing cortical mitochondria from young
E4 mice had lower mitochondrial respiration relative to E3—an effect that worsened with
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age and affected hippocampal mitochondria in aged mice [144]. Interestingly, certain
proteolytic fragments of E4 are known to exhibit mitotoxicity in neurons but has not
observed in astrocytes [39].
Other than the works described herein, one study in particular has investigated
metabolism specifically in astrocytes within the context of APOE, which concluded E4
had reduced mitochondrial metabolism relative to E3 [145]. Similar findings were
described in human APOE mice, reporting mitochondrial dysfunction in E4, while
metabolism was further examined in the entorhinal cortex [144]. Their results show E4
mice had higher levels of malate, citrate, fructose-6-phosphate, and carnitine, and suggests
E4 increases beta oxidation of fatty acids [144].
Although these findings contribute to the body of knowledge surrounding APOE and
brain metabolism, at best they offer rudimentary information on mitochondrial energetics
– by simply measuring the turnover of NADPH – and capture only a single region of the
anesthetized brain. Additionally, any exploration of E2 was absent, which is unfortunately
often the case in most studies examining the metabolic effects of APOE as it could provide
substantial insight into the AD protection conferred by presence of E2. Much of the work
describing the effects of APOE on mitochondria and the metabolic landscape altogether
have been performed either in whole brain tissue or neurons specifically, thus providing
an incomplete perspective as to the influence of APOE on cerebral bioenergetics. Although
astrocytes synthesize the majority of APOE in the CNS, relatively few studies have
investigated isoform-specific effects on metabolism specifically within this critical cell
type.

20

Based on the current literature it is clear E4 brains display glucose hypometabolism
and dysfunctional mitochondria in cognitively normal, young E4 carriers. Given impaired
glucose metabolism and mitochondrial dysfunction precede any clinical or pathological
presentation of AD suggests metabolic impairments are not simply a result of AD
neuropathology but rather appear to contribute in the development of the disease. While
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FDG-PET imaging offers spatial resolution of glucose hypometabolism, it does not

provide information on the specific cell types involved in glucose uptake, nor does it
measure the metabolic fate of glucose. Therefore, determining the APOE-specific
alterations in cerebral metabolism downstream of glucose uptake and astrocyte-specific
metabolic alterations stand to offer valuable insight.
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CHAPTER 2. ORAL GAVAGE DELVERY OF STABLE ISOTOPE TRACER FOR IN
VIVO METABOLOMICS
[This chapter consists of material adapted from a published manuscript: Williams HC, et
al. Oral Gavage Delivery of Stable Isotope Tracer for In Vivo Metabolomics.
Metabolites. 2020 Dec. PMID: 33302448]
2.1

Prologue
A primary goal of the current dissertation project was to characterize the effects of

E2, E3, and E4 on cerebral glucose metabolism by leveraging established targetedreplacement human APOE mouse models. In searching for a method of investigating
glucose metabolism in vivo, potential options included intravenous or intraperitoneal
injections, direct infusions, and dietary incorporation. However, the main consideration
when choosing an in vivo metabolomics approach is utilizing a method which is
physiologically relevant with limited stress to the animal, and importantly, carefully
controls the dose and timing of tracer administration. While the methods identified in the
initial inquiry would collectively address all considerations, no single method was without
limitations. In absence of finding such an approach, I developed a method for utilizing
stable isotope tracers in vivo which was cost-effective, relatively low stress, and
maintained physiological relevance while simultaneously controlling for dosage and
timing. The current Chapter describes the development of this new method, which we
believe provides the field with an important additional tool to study cerebral metabolism
in vivo.

ABSTRACT
Stable isotope-resolved metabolomics (SIRM) is a powerful tool for understanding
disease. Advances in SIRM techniques have improved isotopic delivery and expanded the

workflow from exclusively in vitro applications to in vivo methodologies to study systemic
metabolism. Here, we report a simple, minimally-invasive and cost-effective method of
tracer delivery to study SIRM in vivo in laboratory mice. Following a brief fasting period,
we orally administered a solution of [U-13C] glucose through a blunt gavage needle without
anesthesia, at a physiological dose commonly used for glucose tolerance tests (2 g/kg
bodyweight). We defined isotopic enrichment in plasma and tissue at 15, 30, 120, and 240
min post-gavage.
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C-labeled glucose peaked in plasma around 15 min post-gavage,

followed by period of metabolic decay and clearance until 4 h. We demonstrate robust
enrichment of a variety of central carbon metabolites in the plasma, brain and liver of
C57/BL6 mice, including amino acids, neurotransmitters, and glycolytic and tricarboxylic
acid (TCA) cycle intermediates. We then applied this method to study in vivo metabolism
in two distinct mouse models of diseases known to involve dysregulation of glucose
metabolism: Alzheimer’s disease and type II diabetes. By delivering [U-13C] glucose via
oral gavage to the 5XFAD Alzheimer’s disease model and the Lep ob/ob type II diabetes
model, we were able to resolve significant differences in multiple central carbon pathways
in both model systems, thus providing evidence of the utility of this method to study
diseases with metabolic components. Together, these data clearly demonstrate the efficacy
and efficiency of an oral gavage delivery method, and present a clear time course for 13C
enrichment in plasma, liver and brain of mice following oral gavage of [U-13C] glucose—
data we hope will aid other researchers in their own
design.
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C-glucose metabolomics study

2.2

Introduction
Traditional techniques in targeted metabolomics provide quantitative analysis of

metabolite pools within a selected network, thus offering a snapshot of overall changes in
the metabolome. A more targeted understanding of a specific pathway can be obtained with
a stable isotope labeled substrate, or isotopic tracer, which offers improved specificity for
the pathways and metabolic enzymes involved; for example, identifying metabolites
downstream of glucose metabolism/catabolism when

13

C-glucose is use as the primary

tracer.
Stable isotope-resolved metabolomics (SIRM) couples stable isotope tracing with
nuclear magnetic resonance (NMR) and/or mass spectrometry (MS)-based analyses so that
labeling patterns (isotopomers and isotopologues) of numerous metabolites can be
determined for robust and large-scale reconstruction of metabolic networks [146]. This
approach has been successfully applied to cultured cells, mouse models, tissue models and
human patients [147-149]. SIRM has been applied most heavily in cancer research, where
it has been used to elucidate alterations in metabolic networks associated with different
cancers, as well as rare somatic mutations in isocitrate dehydrogenase [150-152], and
germline lesions in fumarate hydratase [153-155] and succinate dehydrogenase [154, 156,
157].
With added insights through isotopic enrichment, SIRM builds on the foundational
metabolomics methodologies that employ metabolite fractionation by either gas or liquid
chromatography (GC; HPLC), or capillary electrophoresis (CE), followed by mass
spectrometry detection [158]. An important consideration when designing a SIRM study
is selecting the appropriate tracer substrate. Selection of the appropriate stable isotope (e.g.,
13

C, 15N, 2H, 18O, 34S) and substrate (e.g., glucose, lactate, glutamine, etc.) should rely upon
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the desired pathway to be investigated; and more selective analysis of specific nodes of
interest within pathways can be resolved with specific number and position of stable
isotopes. For example, [U-13C] glucose provides broad incorporation throughout central
carbon metabolism pathways, while [1,2-13C] glucose provides specific resolution of
oxidative and non-oxidative branches of the pentose phosphate pathway (PPP). A
description of current stable isotope tracers and their respective utilization(s) is reviewed
in detail by Jang, et al. [159]. The unique information gained through tracer metabolomics
can be a powerful tool for biomarker identification and drug discovery, and aids in both
disease profiling as well as mechanistic studies by providing a critical measure of the
functional outcome from a given biological system.
While the majority of SIRM experiments are conducted in vitro, a variety of delivery
methods have also been successfully applied to stable-isotope tracing in vivo. These include
single or repeated injections of isotopic tracers via intraperitoneal (IP) injection, or direct
injection into the circulation via intravenous (IV) infusion [160-163]. While these methods
are cost-effective, they sacrifice the physiological absorption and metabolism for substrates
that are normally ingested. Continuous infusions of the isotopically labeled substrate
through cannulation is another common approach [164], as it offers the benefit of increased
depth of labeling in more complex metabolic pathways and simpler interpretation as a
result of achieving constant isotopic enrichment (i.e., isotopic steady state). However, the
primary drawbacks of infusion methods are the significant invasiveness of the procedure,
the high level of technical complexity required, and throughput limitations due to the long
time periods required to test each individual animal. Alternatively, oral administration
through ad libitum feeding of a diet in which the isotope has been incorporated has the
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advantages of being non-invasive, less stressful, and conducive to allowing the organism
to reach isotopic steady state with ad libitum feeding over 16+ hours [165]. However, it is
impossible to control for differences in the timing and amount of food intake in this ad
libitum setting. The method also requires customized animal feed and relatively large
amounts of isotopic label, and is thus quite expensive compared to other methods.
While no administration method is without drawbacks, isotope delivery via an oral
gavage is an attractive strategy to mitigate several of the common limitations described
above. The method is simple, minimally invasive, and requires low amounts of isotopic
tracer. A handful of studies have employed an oral gavage to deliver

13

C tracers, mainly

fatty acids [166-169] and carbohydrates [170-173]. For example, one study examined 13C
enrichment into glycogen following oral gavage of glucose [171], while another examined
13

C enrichment in liver, small intestine, and skeletal muscle following oral gavages of a

1:1 mixture containing labeled fructose and unlabeled glucose or vice versa [173]. Here,
we detail a simplified, cost-effective method of 13C isotope delivery based on the glucose
tolerance test performed routinely in mouse models. This method produces robust isotopic
distribution, with the added advantage of speed and consistency to improve rigor and
reproducibility. We provide a detailed time course and labeling patterns for one of the most
commonly used tracer substrates, [U-13C] glucose, in the plasma, liver and brain. Finally,
we apply our method in two distinct mouse models of disease that feature metabolic
components, demonstrating lower
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C-glucose enrichment in glycolysis in the Lepob/ob

model of type II diabetes, and decreases in de novo neurotransmitter synthesis in the
5XFAD mouse model of Alzheimer’s disease.
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2.3

Materials and methods
2.3.1

Animals

All animal procedures were performed in accordance with institutional regulations
and the institutional animal care and use ethics committee at the University of Kentucky
College of Medicine (Protocol #2016-2569; approval date: March 01, 2020). Female wild
type (WT) mice of C57BL/6 background (14 weeks old), ordered from the Jackson
Laboratory (Bar Harbor, ME, USA) were housed in a climate-controlled environment with
a 14/10-h light/dark cycle with water and regular chow diet ad libitum. Sex- and agematched Lepob/ob (ob/ob), ordered from the Jackson Laboratory (Bar Harbor, ME, USA),
were used as a liver glucose metabolism comparison to WT mice. Sex- and age-matched
homozygous 5XFAD, ordered from the Jackson Laboratory (Bar Harbor, ME, USA), mice
were used for behavioral testing and metabolomics analysis as a comparison to WT mice.

2.3.2 Gavage of [U-13C] glucose solution
[U-13C] Glucose (Cambridge Isotope Laboratories, Tewksbury, MA, USA) was
dissolved in ddH2O (Millipore Milli-Q, Bedford, MA, USA) based on the average mouse
cohort bodyweight (2 g [U-13C] glucose/kg bodyweight), based on diabetic glucose
tolerance testing. Mice were fasted for 2–4 h then administered a 250 µL volume of glucose
solution via oral gavage. Blood and tissues (brain and liver) were collected 15 min, 30 min,
2 h, or 4 h post-gavage, detailed below. Blood and tissue were also collected from mice
following starvation period (no gavage) and 4 h following either saline or non-labeled
glucose gavage for use as controls for 13C labeling and gavage protocol.
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2.3.3

Plasma and tissue collection

Following respective post-gavage incubation periods, mice underwent cervical
dislocation and decapitation after which brain and liver were promptly removed and frozen
in liquid nitrogen. Blood was collected via trunk bleed into tube containing 0.5 M EDTA
(Thermo Fisher Scientific, Waltham, MA, USA) and kept on ice until plasma was separated
via centrifugation at 1300 × g for 10 min at 4 °C. The plasma layer (supernatant) was
collected in two aliquots then flash frozen in liquid N2 until derivatization protocol,
detailed below. Following prompt removal of brain and liver, tissues were washed in PBS
(Bio-Rad, Hercules, CA, USA) twice, then ddH2O and quickly blotted dry before
submersion in liquid N2, and stored at −80 °C until further processing.

2.3.4

Glucose colorimetric assay

Blood glucose concentrations were measured in plasma samples from WT mice
using a glucose colorimetric assay (Cayman Chemical, Ann Arbor, MI, USA). The
procedure was conducted according to manufacturer’s protocol. Briefly, plasma samples
were thawed on ice then a volume of 15 µL per sample and manufacturer’s standards were
added to a 96-well plate followed by addition of 85 µL assay buffer. Following addition of
enzyme mixture, 100 µL, the plate was incubated for 10 min at 37 °C. After which a plate
reader was used to read the absorbance at 510 nm and sample absorbances were compared
with the standard curve to determine concentrations.

2.3.5

Triglyceride assay

Blood and liver triglyceride concentrations were measured in WT and Lep ob/ob
using a triglyceride colorimetric assay (Cayman Chemical, Ann Arbor, MI, USA). Plasma
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samples were thawed on ice and diluted 1:9 with sodium phosphate assay buffer. Liver
samples were thawed on ice and approximately 150 mg was finely minced and
homogenized in 1 mL of diluted NP40 reagent containing proteinase inhibitors provided
by the manufacturer. The remaining procedure was conducted according to manufacturer’s
protocol. Briefly, liver samples were centrifuged at 10,000 × g for 10 min at 4 °C, then the
supernatant was diluted 1:4 with NP40. A volume of 10 ul was used for samples and
triglyceride standards followed by addition of reaction mixture and 15 min incubation at
room temperature. The absorbance at 540 nm was read using a plate reader at 540 nm and
sample absorbances were compared with the standard curve to determine concentrations.

2.3.6

Sample preparation for GCMS analysis

All tissues were handled on liquid nitrogen when removed from cryostorage at −80
°C. Brain and liver samples were removed from cryostorage and pulverized to 10 µm
particles in liquid N2 using a Freezer/Mill Cryogenic Grinder (model 6875D, SPEX
SamplePrep, Metuchen, NJ, USA). Eighty microliters of plasma were extracted with 80
µL HPLC-grade MeOH (containing 40 µM L-norvaline [Sigma-Aldrich, St. Louis, MO,
USA] for internal standard; Sigma-Aldrich, St. Louis, MO, USA). Approximately 60 mg
of powdered tissue was removed with a micro spatula to a new tube and extracted with
50% MeOH (20 µM L-norvaline). Following addition of MeOH, mixtures were placed on
ice for 20 min and briefly vortexed at 5 min intervals. Following centrifugation at 24,000
× g for 10 min at 4 °C the aqueous phase containing polar metabolites was isolated to a
separate tube, the resulting pellet briefly dried at 10−3 mBar using a SpeedVac (Thermo
Fisher Scientific, Waltham, MA, USA) to evaporate remaining MeOH then reconstituted
in RIPA buffer (Sigma-Aldrich, St. Louis, MO, USA) followed by BCA Protein Assay Kit
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(Pierce; Thermo Fisher Scientific, Waltham, MA, USA) for protein concentration. The
polar metabolites were dried at 10−3 mbar followed by derivatization. The dried polar
metabolite pellet was derivatized by a two-step methoxyamine protocol first by addition of
50 µL methoxyamine HCl (Sigma-Aldrich, St. Louis, MO, USA) in pyridine (20 mg/mL;
Sigma-Aldrich, St. Louis, MO, USA) followed by 60 min dry heat incubation at 60 °C.
Samples were then transferred to v-shaped glass chromatography vials (Agilent
Technologies, Santa Clara, CA, USA) and sequential addition 80 µL N-methyltrimethylsilyl-trifluoroacetamide (MSTFA; Thermo Fisher Scientific, Waltham, MA,
USA) followed by 60 min dry heat incubation at 60 °C. The samples were allowed to cool
to room temperature then analyzed via GCMS.

2.3.7

GCMS quantitation

GCMS (Agilent Technologies, Santa Clara, CA, USA) protocols were similar to
those described previously [174, 175] except a modified temperature gradient was used for
GC: Initial temperature was 130 C, held for 4 min, rising at 6 C/min to 243 C, rising at
60 C/min to 280 C, held for 2 min. The electron ionization (EI) energy was set to 70 eV.
Scan (m/z: 50–800) and full scan mode were used for metabolomics analysis. Mass spectra
were translated to relative metabolite abundance using the Automated Mass Spectral
Deconvolution and Identification System (AMDIS) software matched to the FiehnLib
metabolomics library (available through Agilent) for retention time and fragmentation
pattern matching with a confidence score of >80 [158, 176-178]. Quantitation was
performed and corrected for natural abundance using the Data Extraction for Stable
Isotope-labelled metabolites (DExSI; https://github.com/DExSI/DExSI) with a primary
ion and at least 2 or more matching qualifying ions. Relative abundance was corrected for
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recovery using L-norvaline and adjusted to protein input from BCA measure to correct for
any differences in tissue quantity used for extraction.

2.3.8 Metabolomics data analysis
Fractional enrichment of each metabolite was calculated as the relative abundance
of each isotopologue relative to the sum of all other isotopologues. Pathway distribution
analysis was determined for glycolysis, TCA cycle, amino acid, and neurotransmitter
synthesis pathways and calculated as the average percentage of 13C-labeled isotopologues
(m+1 + m+2 … + m+n) of metabolites within each pathway relative to the 13C enrichment
across all other pathways. For volcano plot, principal component analysis, fold enrichment
plot

and

pathway

impact

analyses,

the

online

tool

Metaboanalyst

(https://www.metaboanalyst.ca) was used. For pathway impact analysis, data were filtered
using interquartile range (IQR) function and scaled using auto-scaling, in which meancentered values were divided by the standard deviation of each variable. Global test’ and
‘Relative Betweenness Centrality’ parameters were used to determine metabolic pathway
‘hub’ importance.

2.3.9

Animal cognitive testing

Cognitive function was tested in WT and 5XFAD mice using a Morris water maze
as previously described [179]. Trials were performed in a black pool (diameter 121.5 cm)
filled with opaque water with a temperature of 22 °C and lighting between 41.0 and 43.0
lux. Mice were individually housed and allowed to acclimate to cages for 30 min prior to
trial start. Mice were given two sessions per day, and each session consisted of two trials.
Each session was separated by 3 h, and each trial by 10 min. Over a 4-day span, mice were
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trained during “Hidden Platform” trials to locate an “escape” platform (diameter 10 cm)
submerged just under the surface of the water in the “target” quadrant. “Hidden Platform”
trials lasted 60 sec, or until the mouse located the platform and remained on it for 3 sec.
The drop location (where the mice were placed into the maze) was randomized for each
trial, and never included a location within the “target” quadrant. For all consecutive
“Hidden Platform” trials, the platform location was not changed. Visual cues (38 × 38 cm)
were placed at the borders of each quadrant for reference. Spatial memory was assessed 72
h following completion of the “Hidden Platform” trials. During the “Probe” trial, the
hidden platform was removed, and spatial memory was assessed by measuring cumulative
distance from the platform location. Mice then received 2 more days of “Hidden Platform”
training followed by a second “Probe.” Upon completion of the final “Probe” trial, mice
received 2 “Visible Platform” trials with a colored flag (height of 18 cm) cue placed on the
platform. All trials were recorded with a camera and analyzed using Ethovision XT
(Noldus Information Technology, Leesburg, VA, USA).

2.3.10 Statistical analysis
All data are expressed as mean values +/− standard error. Comparisons between
two groups were analyzed by unpaired, two-tailed t-test or multiple unpaired, two-tailed ttests (one per row) for comparisons with multiple isotopologues. Multiple time points
(animal cognitive testing) were analyzed using ANOVAs or repeated measures ANOVA
(time × groups). Statistical significance was determined using an error probability level of
p < 0.05 corrected using the two-stage linear step-up procedure of Benjamini, Krieger and
Yekutieli, with Q = 1%. Statistical details can be found in figure legends for each figure,
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all statistical analyses were calculated using GraphPad Prism 8 software (GraphPad
Software, San Diego, CA, USA).

2.4

Results
2.4.1

Experimental workflow and stable isotope tissue distribution

For the current experimental workflow, universally labeled ([U-13C]) glucose was
delivered to fasted mice (C57BL/6) via oral gavage (2 g/kg bodyweight). At select time
points (15 min, 30 min, 2 h, or 4 h post-gavage), tissues were harvested and prepared for
analysis by gas chromatography mass spectrometry (GCMS) (Figure 2.1a). Total plasma
glucose concentrations followed an expected time course following the

13

C-glucose

gavage, with a peak concentration around 15 min and a return to baseline (fasting)
concentrations after 4 h (Figure 2.1b). Quantification of 13C-glucose in the plasma showed
that by 15 and 30 min, >50% of plasma glucose was fully labeled (13C6; m+6), and by 4 h
post-gavage <5% of circulating glucose was fully labeled (Figure 2.1c). We next examined
13

C enrichment of representative metabolites within pathways of glycolysis, TCA, amino

acid and neurotransmitter synthesis in the plasma, liver and brain of mice gavaged with [U13

C] glucose. The pathway distribution analysis (Figure 2.1d) shows the average

enrichment per pathway, represented as donut charts. Distribution of 13C among metabolic
pathways varied greatly by tissue, with the highest incorporation into glycolysis in plasma
and liver, which was prevalent at all time points (Figure 2.1d, first and second row).
However, 13C incorporation in brain 15 min post-gavage was distributed relatively equally
into glycolysis, TCA cycle, amino acid, and neurotransmitter synthesis pathways, while
neurotransmitter synthesis was most prominent at later time points (Figure 2.1d, third row).
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The pathway distribution of 13C within tissues also shifted over time, for example in brain,
where the percent of 13C found in neurotransmitters (glutamate, aspartate, γ-aminobutyric
acid (GABA), and pyroglutamic acid) increased from 23.7% at 15 min to 40.4% at 4 h
(Figure 2.1d, third row). Together, these data show that the described method for

13

C

substrate administration via oral gavage reliably achieves sufficient incorporation into
multiple central carbon pathways (glycolysis, TCA cycle, and amino acid metabolism
pathways) in multiple tissues.

2.4.2

Brain metabolites display varying patterns of 13C labeling

We next examined specific labeling patterns of 13C incorporation in the brain, with
a specific focus on glycolytic and TCA cycle intermediates as well as neurotransmitter
synthesis (Figure 2.2a). The labeling of TCA cycle intermediates can provide information
regarding contributions from the enzymes pyruvate dehydrogenase (PDH), pyruvate
carboxylase (PC), and malic enzyme (ME), which govern pyruvate entry to the TCA cycle
(Figure 2.2a, color coded). PDH liberates one carbon atom from pyruvate as CO2 and
incorporates two carbons (via acetyl-CoA), while PC incorporates all three carbons from
pyruvate. The reversible ‘malic’ enzyme reaction (malate dehydrogenase-decarboxylating)
can generate singly labeled (m+1) isotopologues via conversion of m+1 pyruvate and CO2
to form m+1 malate (and subsequently m+1 oxaloacetate via malate dehydrogenase), that
can be further incorporated into other TCA cycle intermediates [165]. Fractional
enrichment of specific metabolites isolated from whole brain tissue over time are shown in
Figure 2.2b–l. Metabolites associated with glycolysis (glyceraldehyde phosphate [GAP],
pyruvate, lactate, and alanine) displayed the highest enrichment at 15 and 30 min (Figure
2.2b–d). Conversely, the labeling in TCA cycle intermediates generally plateaued at 2 h
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and/or began to decline by 4 h (Figure 2.2f–i). Although technical limitations hinder
measuring oxaloacetate (OAA) directly, aspartate fractional enrichment (Figure 2.2i)
reflects that of OAA due to its equilibrium with aspartate [180]. Additionally, two abundant
neurotransmitters (pyroglutamic acid and GABA) displayed enrichment patterns similar to
their precursor for synthesis, glutamate, with peak enrichment at 2–4 h post-gavage (Figure
2.2j–l). Finally, labeling patterns among pyruvate and citrate can be used as surrogates to
estimate enzyme activity of PDH and PC [166], calculated as (citrate m+2/pyruvate m+3)
and (citrate m+3/pyruvate m+3), respectively. Our data show increased activity of PDH
relative to PC 15 min post-gavage, with decreasing contributions of both enzymes over
time reflecting the passage of the 13C-glucose bolus through the TCA cycle (Figure 2.2m).

2.4.3

Measuring glucose metabolism in an Alzheimer’s disease model

In order to illustrate a potential application of this oral gavage technique, we
examined how cerebral glucose metabolism is affected in the 5XFAD mouse model of
Alzheimer’s disease [181]. Immediately following their final cognitive testing session,
5XFAD mice and age- and sex-matched WT controls were given an oral gavage of [U-13C]
glucose and brain tissue collected for metabolomic analysis after 2 h (Figure 2.3a). The
commonly used 5XFAD model of Alzheimer’s disease shows early and significant
cognitive deficits, as evidenced by decreased performance in a water maze test of spatial
learning and memory (Figure 2.3b–c). Interestingly, brains from 5XFAD mice exhibited
decreased fractional enrichment of fully labeled pyruvate and lactate (m+3), indicative of
a reduction in glycolysis relative to WT mice (Figure 2.3d–e), and further demonstrated by
the reduced labeling in serine denoted by the decreased m+2 isotopologue (Figure 2.3f).
Additionally, glucose-derived synthesis of the neurotransmitters GABA, N-acetylaspartate
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(NAA), and aspartate were significantly reduced in the 5XFAD model relative to the WT
controls (Figure 2.3g).

Importantly, in addition to the quantification and interpretation of stable isotope
enrichment, the datasets generated with this method can also be mined for information from
total metabolic pool sizes (regardless of labeling). To generate a more global view of
metabolism in the 5XFAD brain, we quantified the relative pool size of ~80 readily
identified metabolites and analyzed these data using Metaboanalyst [182]. A principal
component analysis showed that the 5XFAD and WT mice have distinct metabolic profiles
(Figure 2.4a), while a volcano plot highlighted several specific metabolites that were
uniquely altered in the 5XFAD brain (Figure 2.4b). The most substantially altered
metabolites included threonate, adenosine monophosphate (AMP), and malate, which were
all significantly reduced in the 5XFAD brain compared to WT (Figure 2.4c). To determine
which metabolic pathways were most affected, we performed a pathway enrichment
analysis, which highlighted the pentose phosphate pathway (PPP), carnitine synthesis,
pantothenate and CoA biosynthesis, mitochondrial beta oxidation, and fatty acid
metabolism as the most significantly altered pathways between 5XFAD and WT mice
(Figure 2.4d). Finally, a pathway impact analysis showed several major differences
between WT and 5XFAD brain samples, highlighting changes in the concentration of
metabolites considered key nodes within their pathways. Pathways highlighted by this
impact analysis included hexose metabolism (fructose, mannose), purine metabolism, PPP,
and several amino acid processing pathways (β-alanine; glycine, serine and threonine;
alanine, aspartate and glutamate; valine, leucine and isoleucine) (Figure 2.4e).
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2.4.4

Liver metabolites display varying patterns of 13C labeling

We also examined

13

C incorporation in the liver, detecting enriched metabolites

across all time points post-gavage. In the liver, glucose that enters glycolysis is actively
further metabolized in pathways such as the TCA cycle and amino acid biosynthesis
(Figure 2.5a). Fully labeled (m+6) glucose-6-phosphate (G6P) was the dominant
isotopologue 15 min post-gavage, and the presence of measurable fractions of other
labelled G6P isotopologues suggests a significant amount of 13C scrambling (Figure 2.5b).
Enrichment of pyruvate showed a steady decline in labeling over time after the predominate
isotopologue m+3 peaked at 15 min post-gavage (Figure 2.5c). Lactate and alanine labeling
were more robust than pyruvate, likely a reflection of two processes where the
interconversion of lactate- and alanine-pyruvate (Cori and Cahill cycles) divert pyruvate
for extrahepatic metabolism (Figure 2.5d,e) [183]. Serine m+2 increased in abundance
from 15 to 30 min post-gavage, likely contributed from glycine formed through

13

C

cataplerosis from the TCA cycle (Figure 2.5f). Citrate and malate showed direct labeling
of TCA intermediates, which are used to generate amino acids like aspartate, and as such
they displayed similar fractional labeling patterns (Figure 2.5g-i).

2.4.5

Tracing glucose metabolism in a mouse model of type II diabetes

To illustrate the potential application of this method in a second disease model
system, we used leptin deficient ob/ob mice (Lepob/ob), a common mouse model of obesity
and type II diabetes [184]. We confirmed several phenotypic characteristics of the model
and then employed our method of stable isotope tracer delivery to highlight potential
changes in hepatic glucose metabolism (Figure 2.6a). Lepob/ob mice reliably demonstrate
several features of type II diabetes, including increased adiposity, hyperlipidemia, and fatty
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liver, as reflected by increased bodyweight, plasma triglycerides, and hepatic triglyceride
content measurements (Figure 2.6b–d). To examine specific metabolic perturbations in
Lepob/ob mice, we harvested liver tissue 2 h following gavage of [U-13C] glucose. The
fractional enrichment distribution in several glycolytic intermediates were significantly
altered between Lepob/ob and WT mice. Specifically, Lepob/ob showed decreased m+6 G6P,
m+3 3-phosphoglyercate (3PG), and all labeled isotopologues of lactate (m+1, m+2, m+3;
Figure 2.6e–g). Taken together, these results suggest decreased glucose enrichment in
downstream metabolic products from Lepob/ob mice relative to WT, 2 h after oral gavage of
[U-13C] glucose.

2.5

Discussion
SIRM analysis in vitro has become a widespread methodology to allow a more

targeted interrogation of perturbed metabolic pathways [185]. More recent advances have
allowed the delivery of stable isotope tracers to ex vivo tissue slices , small animals and
even human patients [186]. In vivo SIRM remains a challenging task despite being a very
desirable workflow and is therefore a technique still limited to a select number of
laboratories around the world. In order to facilitate wider adoption of this valuable in vivo
methodology, physiologically relevant cost-effective methods for in vivo metabolomics
analyses are needed. In the current study, we describe a simple, affordable and robust
method of in vivo SIRM in which [U-13C] glucose is delivered to mice via an oral gavage.
We provide a detailed time course of 13C incorporation into the plasma, liver and brain of
mice, and further demonstrate the utility of this technique by highlighting metabolic
changes in two commonly used mouse models of Alzheimer’s disease and type II diabetes.
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In vivo SIRM is inherently complex, as the tissue metabolome is an interconnected
myriad of de novo synthesized metabolites and circulating metabolites as products of
systemic metabolism. Methods of tracer delivery via IV and IP injections or microdialysis
may be more beneficial for use of tracers such as fatty acids or triglycerides, which require
longer term metabolic processing for incorporation into downstream metabolic pathways
within peripheral tissues [187]. However, because direct infusions into circulation or
tissues bypass normal gastrointestinal processing and absorption, some physiological
relevance is sacrificed. While single injections avoid the high cost associated with
continuous infusions, many preliminary trials are often necessary to obtain the optimal time
point after the one-time bolus. Furthermore, the stress due to the inherent invasiveness of
such delivery methods can further complicate results.
Other less-invasive methods currently used for administering tracers in vivo include
various modes of dietary incorporation ad libitum (normal dietary supplementation and
liquid diet). These methods, also detailed by Garcia, et al. [187], retain the physiological
relevance of enteral ingestion lost through direct infusions. Unfortunately, they share the
common problems of low throughput, access to unique expertise, and most importantly
high cost (often upwards of over $300 per mouse). For example, the liquid diet isotopic
tracer delivery method allows SIRM analysis at isotopic steady state beyond central carbon
metabolism, is minimally invasive, and permits ad libitum consumption of tracer [165].
However, there are two major biological drawbacks of this technique. First, the long (14–
24 h) enrichment time allows for extensive isotopic exchange between de novo synthesized
and circulating metabolites and results in isotopic scrambling in host tissues, thus
substantially complicating interpretation. Second, the method is limited to animals with
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normal eating habits, i.e., not sick or behaviorally abnormal. For example, animals that
carry xenografted tumors or overt neurological manifestations cannot be studied using the
liquid diet.
An ideal in vivo delivery method would be cost effective, minimally invasive, with
improved throughput; and we designed the gavage method described herein with all three
parameters in mind. While dosing can easily be modified using the gavage method, the
current experimental design was based on the principle of the commonly used oral glucose
tolerance test (OGTT) (2 g of glucose per kg of bodyweight (40 mg/animal of 20 g)). This
dose is based on clinical tests routinely performed on humans [188], and is commonly used
in mouse studies of obesity, insulin resistance and diabetes [189]. The dietary glucose bolus
is delivered via gavage without trauma or anesthesia [190], and can easily allow analysis
of upwards of 50 animals per day (this study utilized 30 animals over the course of six
hours). Thus, we anticipate that this delivery method will allow greater facilitation and
utilization of in vivo SIRM in the research community. As this method is based off the
OGTT routinely employed in the clinic, we anticipate that similar time course studies can
be conducted in human subjects. Indeed, tracing of

13

C substrates has been applied by

several groups in human studies, as nicely reviewed by Garcia, et al. [187]. A primary
drawback for this approach, however, is that while multiple plasma samples can easily be
harvested and analyzed, analysis of human tissue can only occur ex vivo (as opposed to a
13

C NMR based method) and thus requires collection of excised tissue (ex. surgically

resected tumors or biopsies).
Here, we performed a time course of enrichment from [U-13C] glucose in multiple
tissues, highlighting windows of isotopic distribution and utility to simultaneously
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interrogate multiple organs from a single mouse. We demonstrate the broad applicability
of this method in commonly used mouse models of Alzheimer’s disease (5XFAD) and type
II diabetes (Lepob/ob). We showed how decreased glucose metabolism influences de novo
neurotransmitter synthesis in the 5XFAD mouse model which may correlate with cognitive
deficits. The 5XFAD mouse model has been shown to display glucose hypometabolism,
as detected by a decreased FDG-PET signal [42]. Glucose hypometabolism is a common
feature of AD that can occur in tandem with reduced cerebral blood flow thereby affecting
metabolism by limiting oxygen availability to certain regions [191]. As a cell’s metabolic
activity (and thus the pattern of

13

C enrichment detected in an experimental setting) is

clearly affected by availability of oxygen for mitochondrial respiration, researchers should
consider potential changes in oxygen consumption in their disease model of choice. For
example, reduced mitochondrial respiration has been reported in the brain of 5XFAD mice
[192], and it is possible that these decreases in oxygen consumption are reflected in our
data showing decreased

13

C labeling of neurotransmitters synthesized from TCA cycle

intermediates in 5XFAD mice compared to WT controls. Decreases in glycolysis shown in
the Lepob/ob model are likely attributed to hampered insulin sensitivity and may also result
in part from the increased hepatic and systemic adiposity. Interestingly, we did not observe
striking differences in fractional labeling patterns of TCA cycle intermediates with either
mouse model, which is surprising given the known mitochondrial dysfunction associated
with both the 5XFAD and Lepob/ob mice [193, 194]. However, metabolism of glucose by
the TCA cycle may be further resolved with intermediary time points between 30 min and
2 h as presented herein. Furthermore, as our measurements were taken at early postprandial time points, we did not observe any signs of liver gluconeogenesis in plasma or
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liver. This is likely a reflection of post-prandial activation of pathways of glucose storage
(e.g., glycogenesis). However, analysis of later time points would likely offer more insight
into the gluconeogenic role of the liver.
It should also be noted that any potential differences in TCA cycle intermediates
inherent to either mouse model could be obscured given the rapid onset of tissue hypoxia,
which occurs just seconds post-mortem. Although some degree of tissue hypoxia is likely
unavoidable without a microwave fixation system, it can be mitigated with expeditious
tissue collection. Thus, despite the relatively short period (less than 15 sec) between
euthanasia and freezing of tissue employed in this study, artifactual changes in metabolism
due to tissue hypoxia remain a concern with this and many other in vivo metabolomic
approaches.
Altogether, we detected 80 metabolites across more than 10 metabolic pathways, of
which 15 metabolites involved directly in central carbon metabolism displayed various
isotopic distributions of

13

C enrichment from [U-13C] glucose. When applied to animal

models of disease, the extensive information made available through this method affords
substantial potential in characterizing metabolic networks affected by diseases that may
lead to elucidating metabolic targets for therapeutic interventions. While the GCMS
employed in the current study is relatively affordable, it is limited in the number of
metabolites detected. A more robust mass spectrometer could be used to assess isotopic
enrichment in additional pathways such as the PPP and nucleotide metabolism.
Another limitation is that while we assume minimal invasiveness through previously
established plasma corticosterone levels after gavage [190], we still anticipate an increase
in stress through handling of the mice. However, based on this literature, we expect that
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the stress level is much lower compared to IV/IP injection and/or anesthetized animals—
and can be further mitigated by conditioning the mice through repeated handling. While
this delivery method has great potential to uncover much of the in vivo metabolome, tissue
heterogeneity presents concerns of discerning specific contributions from distinct
subpopulations of cells. Performing metabolomics on cell-sorted populations might
alleviate such concerns, but current techniques are encumbered with metabolism-altering
effects of sorting [195]. Imaging techniques like matrix assisted laser desorption/ionization
(MALDI) and desorption electrospray ionization (DESI) might provide an alternative
solution for tissue heterogeneity through spatial resolution of metabolites in prepared
tissues. Application of MALDI or DESI in tissue obtained from an isotopic enriched animal
could provide unique insight into metabolism at the micro-region and/or cell population
level, representing an important and exciting next step to better understanding the in vivo
metabolome.

2.6

Conclusion
In conclusion, using an oral gavage to administer stable isotope tracers in mice is

an effective tool for studying metabolism in vivo with broad applicability. We demonstrate
a detailed time course for a number of metabolites and metabolic pathways following [U13

C] glucose delivery via oral gavage that shows sufficient incorporation of 13C into major

metabolically active organs. We caution that these data be used as a starting point—a
recommendation to guide future study designs. Many aspects of experimental conditions
(phenotype, pharmacological intervention, and tracer selection) can greatly affect
metabolite turnover rate and isotopic distribution, and researchers should carefully select
parameters with these factors in mind. Future experiments should include gavage of other
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stable isotope tracers such as
and

13

13

C- or 15N-glutamine and other amino acids,

13

C-ketones,

C-fatty acids to trace their distribution and detail their time course. Finally, this

method can be easily adapted further with expanded time points and sequential gavages to
determine flux analyses and nutrient turnover rate of glucose and other tracers.
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Figure 2.1 Experimental design, plasma glucose labeling and 13C pathway distribution
analysis after oral gavage of [U-13C] glucose.
a) Schematic of metabolomics workflow for usage of stable isotope tracer in vivo delivered
via oral gavage. Mice were orally gavaged [U-13C] glucose tracer (2 g/kg bodyweight),
euthanized 15 min, 30 min, 2 h, or 4 h post-gavage, tissues and plasma promptly collected
and frozen in liquid nitrogen. Tissues were machine-ground under liquid nitrogen after
which tissue (or plasma) polar metabolites extracted with MeOH, vacuum dried,
derivatized, and analyzed via GCMS. Data interpreted using AMDIS and DExSI software
for determining pathway enrichment. b) Total plasma glucose was measured via
colorimetric assay to determine plasma glucose concentration pre- and post-gavage (each
time point represents one group of mice). c) Plasma glucose measured via GCMS reveals
labeled versus unlabeled glucose at each time point. d) Pathway distribution analysis of
13
C enrichment within specific metabolic pathways in plasma, liver, and brain. The average
13
C fractional enrichment across representative metabolites from glycolysis, tricarboxylic
acid (TCA) cycle, amino acids, and neurotransmitters were calculated, and shown as the
percent of total 13C enrichment across these pathways for each tissue. Values shown are
mean ± SEM (n = 3–5). Data analyzed by unpaired t-test, p values shown on graph (b).
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Figure 2.2 Carbon tracing in the brain after oral gavage of [U-13C] glucose.
a) Example diagram tracing of glucose carbon through glycolysis, TCA cycle, and
neurotransmitters in whole-brain tissue from mice receiving oral gavage of [U-13C] glucose
(not all possible labeled isotopologues are shown). Carbons are color coded based on the
pathway and/or enzyme from which the carbon was derived. Grey circles: 13C from
glycolysis; green: 13C from pyruvate dehydrogenase (PDH); yellow: 13C from pyruvate
carboxylase (PC); blue, yellow, green tricolor: 13C from malic enzyme (ME), reentry via
ME, PC, or PDH; oxaloacetate (OAA); α-ketoglutarate (α-KG); γ-aminobutyric acid
(GABA). b–l) Fractional enrichment of 13C from glucose over time in the labeled
isotopologues of pyruvate, lactate, Ala, glyceraldehyde phosphate (GAP), citrate,
fumarate, malate, Asp, Glu, pyroglutamic acid, and GABA, respectively. m) Surrogate
enzyme activities were calculated for PDH (citrate m+2/pyruvate m+3) and PC (citrate
m+3/pyruvate m+3) in the brain, showing their respective contributions toward metabolism
of [U-13C] glucose (via pyruvate) into the TCA cycle over time. Values shown are mean ±
SEM (n = 4–5) (b–m). Data analyzed by unpaired t-tests (m). * p < 0.05; ** p < 0.01.
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Figure 2.2 Cerebral glucose metabolism in the 5XFAD Alzheimer’s disease mouse
model.
a) Experimental paradigm depicting the cognitive testing of 5XFAD and WT mice
followed by an oral gavage of [U-13C] glucose, 2 h after which brain tissue was collected
for stable isotope-resolved metabolomics (SIRM). b) Behavioral testing confirms cognitive
impairment of the 5XFAD relative to WT mice, as shown by decreased latency (time to
reach hidden platform) in the Morris water maze. c) Left: Representative heat maps
showing swim paths of 5XFAD and WT during the memory probe of the water maze
(dotted white circle indicates location of the hidden platform; red color indicates areas of
greater activity). Right: 5XFAD mice show a significantly increased distance from the
target during the memory probe, indicating an impairment in long-term memory. d–g)
Fractional labeling patterns of pyruvate (d), lactate (e), and Ser (f) show 13C enrichment in
brain tissue 2 h after oral gavage of [U-13C] glucose. g) Percentage of 13C enrichment in γaminobutyric acid (GABA), Glu, n-acetylaspartate (NAA), and Asp indicate de novo
synthesis of neurotransmitters from glucose (shown as percent of average labeled
isotopologues in WT). Values shown are mean ± SEM (n = 6–7). Data analyzed by repeated
measures ANOVA (b), unpaired t-test (c,g), and multiple t-tests (d–f). * p < 0.05; ** p <
0.01.
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Figure 2.3 Non-tracer metabolomics analysis.
a) Principle component analysis distinguishes between the metabolic profile of 5XFAD
brain from WT based on 80 metabolites identified by GCMS analysis. b,c) A change
volcano plot separates metabolites based on degree of change versus statistical significance
among 5XFAD and WT (b), and select metabolites identified in Figure 2.4b are further
highlighted in (c) by direct comparison of their relative abundance. d) Fold-enrichment
analysis compares the major metabolic pathway differing between 5XFAD and WT. e)
Pathway impact analysis provides a multi-dimensional illustration of metabolic pathways
based on pathway enrichment analysis, pathway topology analysis, and statistical
significance. Values shown are mean ± SEM (n = 6–7) (c). Data analyzed by unpaired ttest (c). * p < 0.05; ** p < 0.01.
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Figure 2.4 Carbon tracing in the liver after oral gavage of [U-13C] glucose.
a) Diagram tracing of glucose through central carbon metabolism pathways in the liver.
Not all possible labeled isotopologues are shown. Grey circles: 13C; white circles: 12C. b–
i) Fractional enrichment of 13C from glucose over time in the labeled isotopologues of
glucose-6-phosphate, pyruvate, lactate, Ala, Ser, citrate, malate, and Asp, respectively.
Values shown are mean ± SEM (n = 4–5).

50

Figure 2.5 Liver glucose metabolism in the Lepob/ob (ob/ob) obesity and type II diabetes
mouse model.
(a) Experimental paradigm depicting ob/ob and WT mice receiving oral gavage of [U-13C]
glucose, 2 h after which tissues and plasma were collected. b) Bodyweight measurement
shows greater body mass of ob/ob mice relative to WT. c,d) Triglyceride levels measured
via colorimetric assay reveals increased plasma (c) and liver (d) triglycerides levels in
ob/ob mice. e–g) Fractional labeling patterns in glucose-6-phosphate (e), 3phosphoglycerate (3PG; f), and lactate (g). Values shown are mean ± SEM (n = 4–5). Data
analyzed by unpaired t-test (b–d) and unpaired, multiple t-tests (d-e). * p < 0.05; ** p <
0.01; *** p < 0.001.
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CHAPTER 3. APOE ALTERS GLUCOSE FLUX THROUGH CENTRAL CARBON
PATHWAYS IN MICE AND ASTROCYTES
[This portion of the chapter consists of material adapted from the published manuscript:
Farmer BC, Williams HC, et al. APOE4 lowers energy expenditure in females and
impairs glucose oxidation by increasing flux through aerobic glycolysis. Mol.
Neurodeger. 2021 Sep. PMID: 34488832]

3.1

Prologue
3.1.1

Background

The following stable isotope metabolomics experiment was conducted in human
APOE mice (homozygous E2, E3, or E4) utilizing a [U-13C] glucose tracer via the oral
gavage method described in the preceding chapter. The experiment was designed to test
whether APOE affected glucose utilization in the brain, specifically in metabolic pathways
downstream of glucose uptake. The literature surrounding E4 during the inception of this
experiment had established cerebral glucose hypometabolism in E4 carriers and animal
models alike, while E2 generally reflected an opposing trend compared to E3. Based on
the general consensus from those findings, I anticipated an isoform-specific effect would
occur with glucose utilization in a similar fashion where E2>E3>E4. Specifically, I
hypothesized E4 would show widespread impairments in glucose utilization throughout
central carbon metabolism pathways, especially in the TCA cycle, that would be indicated
by reduced incorporation of 13C.

3.1.2

Results

To determine the APOE-specific effects on cerebral glucose metabolism, a bolus of
[U-13C] glucose was administered via oral gavage to E2, E3, and E4 mice (aged 10-14

months). Two hours post-gavage, brains were removed and analyzed for 13C incorporation
from glucose into central carbon metabolism pathways. E4 mice showed greater

13

C

enrichment in the late-stage glycolytic intermediates pyruvate and lactate, relative to E2
and E3 (Figure 3.1A,B). Among metabolites involved in the TCA cycle, E4 mice had the
lowest unlabeled (m+0) fraction where E3 had the highest, with exception of aspartate
which did not differ between E2 and E3 (Figure 3.1C-I). The

13

C distribution in citrate

showed an increased m+3 isotopologue in E4 mice relative to E2 and E3 (Figure 3.1C).
The m+3 isotopologue of malate was also higher in E4 relative to E2, while the m+2
isotopologue was greater in E4 relative to E3 (Figure 3.1D). Furthermore, E4 showed
higher fractional enrichment in the m+2 and m+3 isotopologues of fumarate, glutamate,
GABA, and pyroglutamate [although not statistically significant in m+3 pyroglutamate (p
= 0.05)] (Figure 3.1D,E,G-I).

3.1.3

Discussion

The decreased unlabeled fractions seen in TCA intermediates from E4 mice
indicate higher fractional enrichment in labeled isotopologues. However, it is important to
note the increased m+2, m+3, and especially m+4 isotopologues of E4 are not universal
among all TCA intermediates nor whether in comparison with E2 or E3 mice. While the
m+2, m+3 and to a lesser extent m+4 isotopologues of certain metabolites are higher in E4
mice, the fractional distribution patterns among TCA intermediates display a subtle, yet
consistent trend of increased fractions in m+3, m+4, and m+5 isotopologues. This pattern
could indicate a decrease in the oxidation of TCA cycle intermediates, reducing CO2 lost
to respiration, whereby

13

C would accumulate with multiple turns of the TCA cycle.

However, an increase of carbon entry into the TCA cycle through the non-cataplerotic
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enzymes pyruvate carboxylase and malic enzyme would also produce a pattern with a
greater fraction of more enriched isotopologues.

3.1.4
E4 mice showed greater

13

Conclusion

C incorporation from glucose into the late stages of

glycolysis and the TCA cycle, including amino acids derived therefrom. However, as these
results were obtained from whole brain tissue, there are many different metabolically active
cell types that are likely contributing to the brain metabolome. The majority of glucose
taken up by the brain is initially metabolized by astrocytes, which are effectively the hub
of cerebral glucose metabolism and are at least as abundant as neurons, if not more [196].
As astrocytes have a central role in the metabolism of glucose and are the main producers
of APOE in the brain, I sought to measure glucose metabolism specifically in astrocytes.
To determine whether these metabolic differences observed in the brain were also present
in astrocytes, I performed the following set of experiments in E2, E3, and E4 astrocytes
and anticipated the isoform-specific effects on glucose utilization I previously observed
would be more prevalent in astrocytes if they were driving such metabolic alterations.
[This portion of the chapter consists of material adapted from the published manuscript:
Williams HC, et al. APOE alters glucose flux through central carbon pathways in
astrocytes. Neurobiology Dis. 2020 Mar. PMID: 3193114]

ABSTRACT
The Apolipoprotein E (APOE) gene is a major genetic risk factor associated with
Alzheimer's disease (AD). APOE encodes for three main isoforms in humans (E2, E3, and
E4). Homozygous E4 individuals have more than a 10-fold higher risk for developing lateonset AD, while E2 carriers are protected. A hallmark of AD is a reduction in cerebral
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glucose metabolism, alluding to a strong metabolic component in disease onset and
progression. Interestingly, E4 individuals display a similar regional pattern of cerebral
glucose hypometabolism decades prior to disease onset. Mapping the metabolic landscape
may help elucidate the underlying biological mechanism of APOE-associated risk for AD.
Efficient metabolic coupling of neurons and glia is necessary for proper neuronal function,
and disruption in glial energy distribution has been proposed to contribute to neuronal cell
death and AD pathology. One important function of astrocytes – canonically the primary
source of apolipoprotein E in the brain – is to provide metabolic substrates (lactate, lipids,
amino acids and neurotransmitters) to neurons. Here we investigate the effects of APOE
on astrocyte glucose metabolism in vitro utilizing scintillation proximity assays, stable
isotope tracer metabolomics, and gene expression analyses. Glucose uptake is impaired in
E4 astrocytes relative to E2 or E3 with specific alterations in central carbon metabolism.
Using [U-13C] glucose allowed analyses of astrocyte-specific deep metabolic networks
affected by APOE and provided insight to the effects downstream of glucose uptake.
Enrichment of 13C in early steps of glycolysis was lowest in E4 astrocytes (highest in E2),
while synthesis of lactate from glucose was highest in E4 astrocytes (lowest in E2). We
observed an increase in glucose flux through the pentose phosphate pathway (PPP), with
downstream increases in gluconeogenesis, lipid, and de novo nucleotide biosynthesis in E4
astrocytes. There was also a marked increase in

13

C enrichment in the TCA cycle of E4

astrocytes – whose substrates were also incorporated in biosynthesis pathways at a higher
rate. Pyruvate carboxylase (PC) and pyruvate dehydrogenase (PDH) are the two main
enzymes controlling pyruvate entry to the TCA cycle. PC gene expression is increased in
E4 astrocytes and the activity relative to PDH was also increased, compared to E2 or E3.
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Decreased enrichment in the TCA cycle of E2 and E3 astrocytes is suggestive of increased
oxidation and non-glucose derived anaplerosis, which could be fueling mitochondrial ATP
production. Conversely, E4 astrocytes appear to increase carbon flux into the TCA cycle
to fuel cataplerosis. Together, these data demonstrate clear APOE isoform-specific effects
on glucose utilization in astrocytes, including E4-associated increases in lactate synthesis,
PPP flux, and de novo biosynthesis pathways.

3.2

Introduction
There is a well-established association between late-onset Alzheimer’s disease (AD)

and glucose metabolism. For example, AD patients display regional cerebral glucose
hypometabolism as determined by 18-fluorodeoxyglucose positron emission tomography
(FDG-PET), primarily in the posterior cingulate, parietal, and temporal cortices [197, 198].
Clinical late-onset AD symptoms essentially never occur without glucose hypometabolism,
and the extent of these metabolic changes are strongly correlated with the severity of
clinical symptoms [199-201]. Additionally, postmortem metabolomics studies of AD
brains often reveal alterations in glucose utilization and amino acid metabolism [202-204].
While many mysteries remain, much has been learned about cerebral metabolism
over the past several decades, including a greater appreciation for the critical role astrocytes
play in supporting neuronal function [205]. Central to this neuron-astrocyte metabolic
coupling is the astrocytic utilization of glucose—the primary energy substrate for the
brain—to both support their own metabolic needs as well as those of neurons [205].
Glucose metabolism in astrocytes begins with uptake of glucose from the cerebral
vasculature. Upon entry, glucose is phosphorylated to glucose-6-phosphate (G6P) via
hexokinase enzymes. G6P is then shunted to one of three main pathways: i) it is
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incorporated into glycolysis, ii) enters the pentose phosphate pathway (PPP), or iii) is
stored as glycogen [206]. Glycolysis predominates as the main pathway for glucose
metabolism in astrocytes, which generates ATP, NADH, and pyruvate or lactate [205, 207].
Lactate is thought to be shuttled to neurons as part of the astrocyte-neuron lactate shuttle.
Pyruvate can be further metabolized in the TCA cycle to produce additional reducing
equivalents that drive the electron transport chain for ATP production via oxidative
phosphorylation, or for generation of amino acids utilized in biosynthesis and
neurotransmitter synthesis [208, 209]. PPP activity utilizes glucose to regenerate NADPH,
an essential cofactor for both cellular redox management and in the biosynthesis of
nucleotides and lipids. Finally, the role of glycogen metabolism in astrocytes has recently
been broadened beyond a simple description as a glucose reserve during hypoglycemic
states to include several essential functions in regards to memory formation and
consolidation with implications in AD [206, 210, 211].
Importantly, disruption of any of the astrocyte-initiated glucose pathways described
above can result in impairments in neuronal function [212]. This fact may be reflected in
epidemiological studies, as cerebral glucose hypometabolism precedes onset of late-onset
AD in several high-risk groups [133, 213]. This includes carriers of the ε4 allele of
apolipoprotein E (APOE) – the single strongest genetic risk factor for late-onset AD – in
which “AD-like” regional patterns of glucose hypometabolism have been described as
early as the second decade of life [139]. APOE exists in humans as three main isoforms in
humans (E2, E3, and E4), with E4 – which is expressed by nearly 20% of the population –
conferring up to a 15-fold increase in AD risk for homozygotes [214, 215]. Conversely, E2
carriers (approximately 10% of the population) have a substantially lower risk of AD, and
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show slower mental decline and increased longevity [215-219]. While multiple cell types
can synthesize APOE, astrocytes produce the majority of the CNS pool of the protein under
normal conditions [39].
While multiple studies show decreased FDG uptake in E4 carriers, the broader
relationship between APOE and cerebral metabolism is complicated by findings from
fMRI-based studies, as well its potential associations with amyloid pathology. In regards
to the latter, some studies show a strong association between E4 and amyloid deposition
on cerebral glucose uptake [220], others a weak association [221], while yet others show
that APOE’s association with cerebral glucose uptake is independent of amyloid [222].
Additionally, several fMRI-based analyses of E4 carriers show that E4 alters resting state
connectivity and that E4 carriers have elevated baseline activity [223, 224], particularly in
the hippocampus and areas of the default mode network [46]. Mouse models of human
APOE also reflect this complicated picture, with some studies showing reduced cerebral
glucose uptake in E4 expressing mice [129, 225], while others show regional hyperactivity
and metabolic changes [226] and increased glucose uptake in old E4 mice, compared to
those expressing E3 [227]. Intriguingly, some of these seemingly contradictory findings
may be explained by viewing E4 carriage as a case of antagonistic pleiotropy, whereby
potentially advantageous early life alterations in activity and connectivity result in
detrimental metabolic changes in later life [228].
One limiting factor in the pursuit of elucidating the role of APOE is that while PET
imaging provides information on the regional uptake of glucose, it is not sufficient to
distinguish downstream metabolic pathways (i.e. how that glucose is being utilized) nor
does it have the resolution to determine cell specificity (i.e. by what cell types). Discerning
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these two key pieces of information in the context of APOE genotype may help elucidate
the missing link between AD risk and glucose hypometabolism. Previously used
methodologies to identify metabolic changes in AD and cognitively impaired brains are
various metabolomics-based approaches [229, 230]. However, while traditional
metabolomics approaches are able to provide a valuable snapshot of the metabolic
pathways involved, they are unable to identify the precursor-product relationships that
drive such perturbations. This type of precursor-product “tracing” of metabolites through
various pathways is only possible with methods such as stable isotope resolved
metabolomics (SIRM) [231].
In the current study, we employed SIRM to study astrocyte glucose metabolism by
tracing universally labeled 13C glucose ([U-13C] glucose) in astrocytes expressing human
E2, E3, or E4. This

13

C tracer approach allowed us to identify multiple APOE isoform-

dependent alterations in astrocyte central carbon metabolism, including alterations in
glucose flux through glycolysis, PPP, and utilization of the TCA cycle. Specifically,
glycolytic flux in E4 astrocytes indicates larger contributions to the PPP, increased lactate
synthesis, altered patterns of TCA cycle activity and anaplerosis, and an increase in
multiple biosynthetic pathways.

3.3

Materials and methods
3.3.1

Tissue culture and in vitro [U-13C] glucose metabolite labeling

Immortalized astrocytes derived from human APOE targeted-replacement mice
homozygous for either E2, E3, or E4 (kind gift from Dr. David Holtzman) [232]. For the
tracer experiment, astrocytes seeded as triplicates into 10 cm tissue-culture dishes and
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maintained in maintenance media Advanced Dulbecco’s Modified Eagle Media (DMEM)
supplemented with 10% FBS, 4% sodium pyruvate, and 1% Geneticin® (Thermo Fisher
Scientific). At roughly 50% density, maintenance media was removed and cells were
washed three times with sterile PBS. Tracer media (consisting of glucose free DMEM
supplemented with 10 mM [U-13C] glucose (Cambridge), 10% dialyzed FBS and 0.4%
Geneticin®) was then added. Cells were incubated at 5% CO2 and 37 °C for 24 hours in
order to reach isotopic steady state—meaning 13C enrichment into a given metabolite was
stable relative to experimental error [185]. After 24 hours, media was removed and plates
were washed on ice 3X with ice cold PBS. 1 mL of ice cold CH3CN was added and cells
were incubated at -20 °C for 10 min to quench cellular metabolism and initiate cellular
lysis. Plates were then scraped and cellular lysates collected in cryovials, snap frozen in
liquid nitrogen, and then stored at -80 °C until mass spectrometry analysis. Total cellular
protein was measured using a BCA Protein Assay Kit (Thermo). Reported values were
normalized to protein isolated from corresponding well.

3.3.2

Interpretation of 13C fractional labeling

To gain insight into the intracellular fate of glucose in astrocytes expressing human
E2, E3, or E4, we analyzed the distribution of a [U-13C] glucose tracer into 117 distinct
metabolites using an ion chromatography (IC) mass spectrometry (MS) approach [149,
165, 233], further detailed below, to determine the intracellular fate of glucose in vitro
(Figure 3.2A).
Glucose tracing data is represented as fractional enrichment, which reflects the
percent of each isotopologue contribution to the metabolite’s total pool. Isotopologues are
defined as compounds that only differ in their isotopic distribution. M+0 represents a
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metabolite containing zero 13C atoms, while m+1 contains one 13C atom and so on and so
forth. This is graphically represented in Figure 3.2B. These fractional labeling patterns
provide information on glucose flux through specific pathways as well as estimations of
enzyme activity [185]. For example, the ratio of citrate and pyruvate fractions can serve as
surrogate enzyme activity measures for PDH and PC (PDH: citrate m+2/pyruvate m+3;
PC: citrate m+3/pyruvate m+3) [166]. Following natural abundance correction (see
reference below), we can conclude that the presence of a 13C atom in a given isotopologue
is derived from glucose, as the only source of 13C was from exogenously administered [U13

C] glucose in the cell culture media.

3.3.3

Polar metabolite analysis by Ion-Chromatography Mass Spectroscopy

Samples were prepared and run by the Research Center for Stable Isotope-Resolved
Metabolomics (RCSIRM) at the University of Kentucky. Briefly, samples were thawed on
ice and chloroform was added in a 2:1.5:1 CH3CN to water to chloroform ratio and shaken
vigorously. The samples were then centrifuged at 3,500 x g for 20 min to produce an upper
polar layer of metabolites. Polar metabolites were transferred, lyophilized and reconstituted
in nanopure water. A Dionex ICS-5000+ ion chromatograph interfaced with a Orbitrap
Fusion Tribrid mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA)
operating at a resolution setting of 500,000 (FWHM at m/z 200) was used to identify 13C
isotopologues. The chromatography was performed using a Dionex IonPac AG11-HC-4
μm RFIC&HPIC (2 × 50 mm) guard column upstream of a Dionex IonPac AS11-HC-4 μm
RFIC&HPIC (2 × 250 mm) column. Chromatography and mass spectrometric settings with
an acquisition m/z range of 80 to 700 were the same as described previously [234].
Metabolites and their isotopologues were identified by chromatographic retention times
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and their m/z values compared with those of the standards. Spectra were curated for correct
identification of isotopologues and subsequently integrated and exported via the
TraceFinder 3.3 (Thermo, Waltham, MA, USA) software package. Peak areas were
corrected for natural abundance as previously described [235]. Fractional enrichment was
calculated to quantify 13C incorporation into downstream pathways.

3.3.4

Scintillation proximity assay

Scintillation Proximity Assay (SPA) measures uptake of radioactively labeled
substrates as previously described[236]. Immortalized astrocytes were seeded on Perkin
Elmer Cytostar-T 96-well plates at a concentration of 50,000 cells/well in maintenance
media. Approximately 24 hours after seeding the maintenance media was aspirated and
cells were washed with sterile PBS. Cells were then starved for four hours in starvation
media glucose-free DMEM, 10% FBS, 1 mM sodium pyruvate, 0.4% Geneticin (Gibco) to
promote cell cycle synchrony and maximal glucose kinetics. Following the starvation
period, starvation media was replaced with starvation media containing deoxy-D-glucose,
2-[1,2-3H] (5.6 µCi/mL) and each well was measured in a MicroBeta scintillation counter
(Perkin-Elmer) for 10 sec every 15 min for two hours. Scintillation counts were normalized
to cellular protein as quantified by a commercially available bicinchoninic acid (BCA)
assay kit.

3.3.5 Microarray gene expression
RNA was isolated from in vitro astrocytes using Trizol (Thermofisher) according
to manufacturer’s instructions. Briefly, E2, E3, and E4 immortal astrocytes under identical
culture conditions in maintenance media were washed and treated with Trizol for 5 min to
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accomplish nucleoprotein complex dissociation. Chloroform was then added and samples
were centrifuged at 12,000 x g for 15 minutes to separate RNA from the lower organic
phase. RNA was precipitated with addition of isopropanol, washed with 75% ethanol and
dried briefly. RNA pellets were resuspended in 50 uL of RNAse free water. Total RNA
was reverse transcribed to cDNA using the High Capacity RNA-to-cDNA Kit (Applied
Biosystems) on a SimpliAmp Thermocycler (Applied Biosystems). cDNA was quantified
by NanoDrop and loaded at 100 ng/well into a custom Taqman Gene Array plate with 2X
Taqman Fast Advanced Mastermix and sealed with MicroAmp™ Optical Adhesive Film.
Taqman qRT-PCR was performed over 40 cycles on a QuantStudio 3 Flex Real-Time PCR
System under the following cycle conditions: enzyme activation at 95 °C for 20 sec,
denaturation at 95 °C for 1 sec, and annealing and extension at 60 °C for 20 sec. Ct values
were normalized to housekeeping gene 18S for each plate to obtain ΔCt values. Gene
expression differences were found by comparing to 2-ΔCt values and expressed as
percentage of the mean of E3 samples.

3.3.6

Statistics

All data are expressed as mean values +/- standard error. Comparisons between two
groups were analyzed by two-tailed t-test. Multiple groups and/or multiple time points were
analyzed using ANOVAs (Prism, Graphpad), or repeated measures ANOVA (time x
groups). Statistical significance was determined using an error probability level of p < 0.05
corrected using the two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli,
with Q = 1%.

63

3.4

Results

3.4.1

E4 astrocytes exhibit decreased glucose uptake while E2 have increased uptake
To begin to define the role of APOE in regulating glucose metabolism in astrocytes,

we first measured the rate of glucose uptake in real time using a scintillation proximity
assay (SPA). We observed a clear stepwise APOE effect on the rate of 3H-2DG uptake,
with E4 astrocytes taking up significantly less, and E2 substantially more glucose, when
compared to E3 astrocytes (Figure 3.2).

3.4.2

E4 astrocytes show increased non-oxidative PPP activity and lactate generation
Using a [U-13C] glucose tracer in vitro, we found substantial 13C incorporation into

glycolysis in all APOE isoforms as demonstrated by high levels of

13

C enrichment in all

measured metabolites (>50% for all genotypes) (Figure 3.4). The first step in glucose
metabolism after transport into an astrocyte is phosphorylation to G6P, where E2 astrocytes
displayed the highest fractional enrichment in G6P at m+6 (Figure 3.4B). E4 astrocytes
had the lowest enrichment in G6P at m+6, due to increased fractions at m+3 and m+5. Both
fructose-6-phosphate (F6P) and fructose-1,6-bisphosphate (F1,6BP) labeling show a
similar pattern as G6P, with E4 having the highest m+3 and m+5 fractions while E2 has
the greatest m+6 fraction (Figure 3.4C). We did not observe significant differences
between genotypes in the three-carbon glycolytic intermediates 1,3-bisphosphoglycerate,
2/3-phosphoglycerate, and phosphoenolpyruvate. Interestingly, glucose flux into the late
stages of glycolysis (pyruvate and lactate) was significantly higher in E4 astrocytes. This
is reflected in the increased fraction of fully labeled (m+3) pyruvate and lactate in E4,
compared to E2 and E3 astrocytes (Figure 3.4E-F).
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Notably, we also observed a stepwise APOE effect on 13C enrichment in the nonoxidative stage of the PPP (E2<E3<E4), as evidence by fully labeled (m+5) ribose-5phosphate (R5P) and fully labeled (m+4) erythrose-4-phosphate (E4P) (Figure 3.4D,H).
The last oxidative reaction in the PPP is the production of ribulose 5-phosphate, which can
reversibly isomerize to R5P or alternatively undergo a series of reactions that result in the
production of other pentose phosphates as well as the glycolysis intermediates F6P and
glyceraldehyde-3-phosphate (G3P). The m+5 labeling of F1,6BP, F6P, and G6P likely
reflects re-entry of PPP products into glycolysis via the non-oxidative branch of the PPP
[146], and shows a clear stepwise APOE effect on the rate of PPP contribution to glycolysis
(E2<E3<E4). Similarly, the stepwise (E2<E3<E4) increase in m+3 labeling of the
glycolysis intermediates F6P and G6P reflects gluconeogenesis (reverse glycolysis).
Together, this suggests that compared to E3 astrocytes, E2 astrocytes have increased flux
directly through glycolysis, while E4 astrocytes cycle more glucose through the PPP.

3.4.3

APOE alters TCA cycle activity

To further explore the effects of APOE on glucose metabolism in pathways
downstream from glycolysis, we examined the fractional enrichment of TCA cycle
intermediates and the anaplerotic sites involved therein. Pyruvate entry into the TCA cycle
is facilitated by the enzymes pyruvate dehydrogenase (PDH) and pyruvate carboxylase
(PC), which incorporate either two or three carbon atoms, respectively [237]. Citrate m+2
fraction indicates contributions from PDH, which is highest in E2 and lowest in E4.
Comparing PC activity to PDH activity provides an indication of TCA anaplerosis. E2
astrocytes had the lowest PC:PDH ratio of 0.75, followed by E3 at 0.83 and E4 at 0.89
(Figure 3.5A), suggesting that E4 astrocytes are undergoing more anaplerosis in order to
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replenish the TCA of lost substrates. A higher citrate m+5 in E4 astrocytes also suggests
increased anaplerosis from contributions of both PC and PDH. When utilizing a fully
labeled pyruvate, PC generates oxaloacetate m+3 and when combined with, via citrate
synthase, an acetyl-CoA that is produced from PDH utilizing a fully labeled pyruvate
ultimately produces citrate m+5 (Figure 3.5F). Interestingly, gene expression of PC was
significantly higher in E4 astrocytes compared to E2 and E3 cells (Figure 3.5B).
Additionally, the m+5 fraction of citrate is highest in E4 astrocytes (which have a PC:PDH
ratio close to 1), further suggesting that PC is contributing more to TCA cycle flux in E4
astrocytes than E2 or E3 (Figure 3.5F).
A general overview of the TCA cycle can be obtained from averaging the fractional
enrichments of the entire TCA intermediates. This yields a distribution of all isotopologues
and offers insight to global patterns of the TCA cycle. Higher fractions of m+2
isotopologues in E2 and E3 astrocytes, likely due to increased PDH activity, suggests 13C
input undergoes a single turn of the TCA cycle before being released as

13

CO2 (Figure

3.6C). Multiple turns of the TCA cycle would steadily feed more 13C into the TCA cycle,
sustaining the 13CO2 lost to oxidation. This would result in an increase of the more enriched
isotopologues, as demonstrated by the m+4, m+5, and m+6 fractions of E4 (Figure 3.6CL). Also referred to as reverse Krebs cycle, a reductive TCA cycle operates in the reverse,
or non-oxidative direction to replenish TCA substrates lost to cataplerosis [238].
Cataplerosis is evidenced in E4 astrocytes by increased enrichment of amino acids
synthesized from the TCA cycle, aspartate (m+4) and glutamate (m+4 and m+5) (Figure
3.6E,L). The decreased labeling in m+4, m+5 and m+6 isotopologues of E2 and E3, relative
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to E4, could result from glutamine import and subsequent oxidation via glutaminolysis,
which would contribute unlabeled carbon atoms into TCA intermediates.

3.4.4

E4 astrocytes show increased purine and pyrimidine synthesis

The synthesis of nucleotides from glucose utilizes PPP products to generate the five
membered sugar ring attached to nucleotides. The stepwise APOE-associated increases in
13

C labeling of R5P (E2<E3<E4) (Figure 3.4D) may suggest differences in nucleotide

biosynthesis, as R5P serves as a critical precursor to both purine and pyrimidine
ribonucleotide synthesis. To determine the effect of APOE on the rate of nucleotide
biosynthesis, we next examined the patterns of [U-13C] glucose-derived

13

C in various

purine and pyrimidine nucleotides.
The carbon atoms for de novo biosynthesis of purines come from glycine,
bicarbonate, and the methyl donor formyltetrahydrofolate (fTHF) (Villa et al., 2019). Once
generated, inosine monophosphate (IMP) can then be converted to guanosine or adenine
phosphates. While guanosine monophosphate levels were not significantly different
between genotypes, the amount of both 13C-labeled IMP and 13C-labeled adenosine
monophosphate (AMP) were significantly higher in E4 compared to E2 or E3 astrocytes
(Fig. 3.6A-C). This substantial in- crease in 13C-labeled IMP and AMP suggests that
compared to E2 and E3 astrocytes, cells expressing E4 are diverting significantly more
glucose toward de novo purine nucleotide biosynthesis.
For a broad look at purine and pyrimidine biosynthesis, we ana- lyzed the average
13C labeling patterns for adenine phosphates (AMP, ADP, ATP) and uridine phosphates
(UMP, UDP and UTP) (Fig. 3.6D-E). Synthesis was increased in E4 astrocytes relative to
E2 and E3 as evi- denced by greater m + 7, m + 8, and m + 9 fractions in purine phos67

phates and m + 7 and m + 8 fractions in uridine phosphates. These fractions correspond to
the nucleotide base where either m + 2, m + 3, or m + 4 aspartate was utilized, the latter of
which is also highest in E4 astrocytes (Fig. 3.5D). Conversely, the m + 5 isotopologue of
the uridine phosphates was highest in E2, followed by E3 and then E4 astrocytes (Fig.
3.6E). This fraction denotes labeling in the ribose sugar, suggesting that the majority of
uridine phosphates in E2, and to a lesser extent E3, contain only a newly synthesized ribose
ring along with a recycled or salvaged base. Pyrimidines with deoxyribose sugar rings
(dUMP, dTMP, and dTDP) display a similar pattern of in- creased m + 5 fractions in E2
and E3, suggesting that of the labeled isotopologues the majority contain only a labeled
ribose. In contrast, the labeling pattern in E4 astrocytes indicates an increase in newly
synthesized bases demonstrated by greater fractions of m + 7, m + 8 and m + 9 relative to
E2 or E3 (Fig. 6D-E), suggestive of an E4-associated upregulation of nucleotide
biosynthetic pathways.

3.4.5

E4 astrocytes show increased biosynthesis of glutathione, lipid precursors,
NADH, and UDP hexosamines

Amino acids generated by the TCA cycle are utilized in a variety of biosynthetic
pathways. For example, glutathione is synthesized using TCA-derived glutamate, cysteine
and glycine (derived from serine via glycolytic intermediate 3PG). Interestingly, the
fractional labeling pattern of glutathione m+1 through m+5 mirrors that of glutamate,
where E2 is highest in m+2 and E4 higher in fractions m+4 and m+5 (Figure 3.7A).
Additionally, the m+6 and m+7 fractions, which are indicative of 13C contributions from
glycine, are also increased in E4 astrocytes compared to E2 and E3 (Figure 3.7A). The
absence of fractions m+8, m+9 and m+10 suggest that in all three genotypes cysteine
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utilized for glutathione biosynthesis is not derived from glucose. However, the prominent
m+6 and m+7 fractions seen in E4 suggest a much higher flux of glucose out of glycolysis,
where 3PG is used to synthesize serine and subsequently glycine.
Glycerophosphocholine (GPC) and glycerylphosphorylethanolamine (GPE) are
found in the brain and involved in the phospholipid biosynthesis pathway [239]. The higher
m+3 fractions of both GPC and GPE in E4 astrocytes suggests increased activity of the
phospholipid biosynthesis pathway relative to E2 or E3 (Figure 3.7B-C).
The total amount of labeled NADH was higher in E4 astrocytes relative to E2 or
E3 (Figure 6D). NADH labeling in m+5 and m+10 are increased in E4 and provides
indication of

13

C enrichment from labeled ribose (Figure 3.7E). The m+12, m+13, and

m+14 fractions in NADH are also increased in E4 and indicate labeling in the purine ring
(Figure 3.7E). The nicotinamide ring shows no labeling as it is only synthesized in
astrocytes from essential amino acids [240].
Glucose can be diverted to the hexosamine biosynthetic pathway (HBP), which
culminates in the production of the amino sugars essential for the biosynthesis of
glycosaminoglycans, proteoglycans, and glycolipids. To measure glucose flux into the
HBP, we analyzed the average fractional enrichment patterns of multiple UDPhexosamines (UDP-glucose, UDP-galactose, UDP-N-acetylgalactosamine and UDP-Nacetylglucosamine). The observed increases in the unlabeled m+0 fractions in E2 and E3
astrocytes suggests a higher rate of glycolysis, which has been shown to decrease glucosederived

13

C incorporation into HBP [241] (Figure 3.7F). Conversely, the increased

enrichment in m+14, m+15, and m+16 fractions seen in E4 astrocytes is due to labeling in
the nucleotide base and requires contributions from 13C labeled aspartate (generated from
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TCA intermediates) during pyrimidine biosynthesis. Together, the labeling patterns in
metabolites containing nucleotides in E4 astrocytes show increased 13C enrichment in the
nucleotide bases, both pyrimidines and purines, and their downstream products.

3.5

Discussion
Changes in glucose metabolism have been characterized in E4 carriers for decades,

and several cellular mechanisms have been described to potentially explain these
phenomena. This includes impaired insulin receptor signaling, altered expression of
glucose transporters and mitochondrial proteins, and mitochondrial dysfunction due to E4
proteolysis [242]. However, the majority of these E4-mediated detrimental effects on
metabolic function have been demonstrated in whole brain tissue or neurons, and thus
provide an important but incomplete picture of the metabolic landscape influenced by
APOE, especially in astrocytes (the main source of APOE synthesis in the brain) [28, 243245].
In the current study, we aimed to determine the precise effects of APOE on glucose
utilization in astrocytes. To do so, we traced

13

C atoms from [U-13C] glucose through

multiple central carbon metabolic pathways in astrocytes expressing human E2, E3, or E4.
The approach identified multiple APOE isoform-dependent alterations, including
differences in glucose flux through glycolysis, PPP, and glucose utilization within the TCA
cycle. Specifically, we observed an E4-associated shift in glucose entry into the TCA cycle,
and stepwise APOE effects (E2<E3<E4) on the rate of glucose cycling through the nonoxidative PPP and on glucose flux through pathways of de novo nucleotide biosynthesis.
The differences observed in the labeling patterns of glycolytic intermediates
containing six carbon atoms (F1,6BP, F6P and G6P) suggests that alternative mechanisms
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are contributing to glycolytic activity. E2 astrocytes displaying the highest m+6 fractions
in six-carbon glycolytic intermediates and m+3 fractions in three-carbon intermediates
suggests greater glucose flux directly through glycolysis relative to E3 and E4. Conversely,
E4 astrocytes appear to cycle a higher fraction of glucose through the non-oxidative PPP
and then back into glycolysis via gluconeogenesis. This cycling is evidenced by higher
fractional labeling in the m+3 and m+5 fractions of glycolytic intermediates F1,6BP, F6P
and G6P, respectively.
In the late stages of glycolysis, the decreases observed in glycolytic end products
lactate and pyruvate at m+3 in E2 astrocytes suggest that either i) non-glycolytic sources
of pyruvate and/or lactate (as the two are actively interconverted) are contributing to
metabolite pools, or ii) that E2 astrocytes have a much higher reserve pool of pyruvate
and/or lactate. The first is more likely given that the media was supplemented with
unlabeled pyruvate and that 24 hours has proven sufficient to establish isotopic steady state
of glycolysis during in vitro tracer experiments [231]. Thus, E4 astrocytes appear to have
increased glucose flux into oxygen-independent glycolysis, as evidenced by the
significantly higher fraction of m+3 lactate. However, it should be noted that the decreased
m+3 in pyruvate and lactate relative to other glycolytic intermediates may instead reflect
extracellular pyruvate uptake, as the media was supplemented with sodium pyruvate thus
contributing a source of 12C atoms. Therefore, an alternative explanation for the observed
labeling patterns in pyruvate and lactate is that E4 astrocytes take up and/or utilize less of
this extracellular 12C pyruvate compared to E2 and E3 astrocytes.
The increased m+5 fractions supports entry of PPP intermediates into glycolysis and
are likely derived from ribose-5-phosphate. Recycling PPP intermediates through
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glycolysis to once again enter the PPP might occur in conditions requiring more NADPH,
such as during lipid and nucleic acid biosynthesis, which is increased in certain brain
regions of E4 mice [226]. NADPH is also utilized in glutathione recycling, a major
pathway for mitigating oxidative stress [246]. Under conditions of oxidative stress
astrocytes have been shown to increase PPP activity [247]. AD brains exhibit increased
oxidative damage that correlates with E4 [248]. AD brains with presence of at least one E4
allele also display increased glutathione peroxidase activity, a process that would drive the
need for NADPH production to reduce oxidized glutathione [141]. The switch to a
reductive TCA cycle as opposed to oxidative, results in the generation of less reactive
oxygen species. Perhaps E4 astrocytes initiate a switch to a reductive TCA cycle in order
to mitigate an environment of increased oxidative stress [141, 249-251].
When undergoing oxidative metabolism in the TCA cycle, glutamine can be used to
generate ATP via conversion to alpha-ketoglutarate and subsequently succinate. Using
non-glucose derived glutamine would contribute higher unlabeled fractions, seen in E2 and
to a lesser extent E3. Mice expressing human E4 alleles had decreased brain glutaminase
levels, suggesting altered glutamate-glutamine cycle [252]. Our results showing increased
labeling of TCA intermediates in E4 astrocytes further indicate lower glutaminolysis
activity, as glutamine oxidation would contribute a higher unlabeled fraction. Reductive
carboxylation of glucose – or alternatively, multiple turns of the TCA cycle – would
generate more enriched isotopologues, as evidenced in E4 astrocytes. Also referred to as
reverse Krebs cycle, a reductive TCA cycle operates in the reverse, or non-oxidative
direction to replenish TCA substrates lost to cataplerosis, a potential explanation for the
observed patterns of TCA labeling in E4 astrocytes [238]. Increased TCA cycle activity in
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E4 might result from a shift toward oxidative phosphorylation, which in turn could
contribute to elevated oxidative stress [253]. Thus, undergoing greater oxidative
phosphorylation could be deleterious in E4 cells, given their decreased ability to mitigate
oxidative stress [254]. Oxidative phosphorylation is increased with age, and a
predisposition of E4 to undergo more oxidative phosphorylation may exacerbate oxidative
damage contributing to AD onset [255].
Decreased de novo synthesis of nucleotides from glucose observed in E2, and to a
lesser extent E3, could be due to higher activity of purine and pyrimidine salvage pathways,
thereby mitigating the need to synthesize new nucleotides. The increased conversion of
serine to glycine, as denoted by higher m+6 and m+7 fractions of glutathione in E4
astrocytes, generates a methyl group that can be utilized in nucleotide biosynthesis.
Together, the labeling patterns in metabolites containing nucleotides in E4 astrocytes show
increased

13

C enrichment in the nucleotide bases, in both pyrimidines and purines. This

may suggest either altered nucleotide salvage ability, an increased demand for nucleotides,
or a combination of the two. When taken together with labeling patterns from TCA cycle
intermediates and increased labeling in acetylated metabolites, this may suggest an E4mediated shift toward a cataplerotic TCA cycle, in which substrates are utilized for
biosynthesis rather than driving oxidative phosphorylation.
Our results highlighting APOE-specific alterations in glucose flux into the PPP and
purine biosynthesis pathways in astrocytes are particularly interesting given that these two
pathways are linked to both E4 status and AD. Purine metabolism is dysregulated in the
brains of individuals with mild cognitive impairment (MCI) and AD [256-258], and
postmortem analyses of AD brain tissue also show alterations in PPP metabolites [202,
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230]. Additionally, an untargeted, integrated ‘omics analysis of hippocampal tissue from
mice expressing human E3 or E4 revealed that the top two pathways altered were PPP and
purine metabolism [259]. The PPP plays a critical role in managing cellular redox through
regeneration of NADPH, and dysregulation of this pathway may contribute to the increased
oxidative stress associated with both AD and E4. The PPP also metabolizes glucose to
generate the five-carbon precursors for a variety of biosynthetic reactions, including
purines and NADH biosynthesis. Finally, as the purine adenosine is a critical building
block for ATP generation, deficits in purine biosynthesis may provide a link to help support
the bioenergetic failure hypothesis of AD [260]. The current study provides new insight
into the specific changes in glucose flux within these pathways that may contribute to the
differences in total metabolite concentrations reported in E4 and AD brains [226, 259].
The reduction in glucose uptake observed in E4 astrocytes may suggest an important
role for this cell type in contributing to the cerebral glucose hypometabolism in E4 carriers
observed with PET imaging [261]. Intriguingly, it may also not only contribute to the
reduction in glucose flux through glycolysis but may also drive the increased recycling of
PPP intermediates seen in these cells. Perhaps E4 astrocytes re-appropriate metabolic
intermediates in order to supply substrates for the PPP to facilitate NADPH and
biosynthesis processes.
Our results suggest that E4 astrocytes flux more 13C from glucose to lactate than E2
and E3 astrocytes. This is interesting for a number of reasons. First, studies show that
greater expression of lactate-producing enzymes are correlated with increased memory in
mice, and increased lactate concentrations during neural activity may help explain the
increased cognitive function and alterations in regional brain activation patterns via fMRI
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reported in young and middle-aged E4 carriers [262-265]. A preference for lactate
production in E4 astrocytes would also facilitate more oxygen-independent glycolysis,
which while potentially beneficial for brain function and memory, could contribute to
cognitive decline later in life due to age-related impairments in lactate processing [263].
Interestingly, oxygen-dependent glycolysis decreases with age and may also be altered in
AD [266, 267]. Second, E4 astrocytes were recently shown to carry aberrant endosomes
that are highly acidified, leading to down regulation of Na+ /H+ exchanger 6 and
subsequent impairments in membrane receptor trafficking [268]. Apart from endosomal
pH, cytoplasmic pH of E4 astrocytes was also shown to be lower, though non-significantly
so. We hypothesize that E4 astrocytes may be decreasing their pH based on increased
lactate synthesis from cytoplasmic glycolysis. This, in part, may be mitigated by endosomal
H+ sinks that sequester H+ from the cytoplasm to maintain physiologic pH. This
endosomal acidification then reduces trafficking and surface expression of receptors such
as LRP1, a key receptor for amyloid-β which is known to be decreased in E4 astrocytes
[268]. Additionally, lower pH in itself is considered a post-translational structural modifier
of protein conformation [269]. It has been reported that stability, aggregation, and
lipidation of APOE depends strongly on pH [270]. Specifically, lower pH drives selfaggregation and increases lipid binding. E4 astrocytes display both increased aggregation
of intracellular APOE and increased intracellular lipid content [271, 272]. Addition of
unlabeled lactate to a 13C-glucose treatment decreases the incorporation of isotopic label
into fatty acids by up to 40%, indicating that lactate is a major carbon source and carbon
competitor for fatty acid biogenesis [273].
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Here, we show that glycerophosphocholine and glyceryl-phosphorylethanolamine
are enriched in glucose derived carbons in E4 astrocytes. Furthermore, our group has
shown an increased lipid droplet phenotype in E4 astrocytes, supporting the idea that E4
astrocytes may be managing increased cellular lactate via lipogenic means [272]. Increased
synthesis of GPC observed in E4 astrocytes could result from elevated phosphatidylcholine
hydrolysis, a process mediated by phospholipase A2. The ratios of GPC to choline and GPE
to ethanolamine were increased certain AD brain regions also known to be associated with
glucose hypometabolism [274]. Interestingly, GPC is increased in both cerebrospinal fluid
and brains of AD patients compared to age-matched controls [275, 276]. Amyloid β
peptides have been shown to activate cPLA2, the subtype likely responsible for
phosphatidylcholine hydrolysis in the brain, while the breakdown product GPC was shown
to promote -amyloid aggregation [277, 278].
Although our study provides new detail and insight into APOE-directed changes in
astrocyte metabolism, it has several limitations. First, the model of choice—an in vitro
system immortalized murine astrocyte—may limit extrapolation of our results. While
focusing on one cell type in vitro limits confounding variables—those very confounders
(i.e. the multiple cell types and intricate interplay and interdependence in vivo) are critical
to the ultimate translation of these findings to the E4 and AD human brain. Second, while
we also focused on a 24 hour timepoint in order to reach a steady state of 13C incorporation,
this extended timeline may cause us to miss other potential APOE effects in pathways like
glycolysis that occur very quickly. Finally, our study focused solely on 13C-labeled glucose
as an energy source. Although astrocytes are thought to primarily rely on glucose for ATP
production, they are known to metabolize numerous other substrates for energy production
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(fatty acids, glutamine, and glycogen-derived glucose) [207]. Contributions from these
non-glucose sources could be contributing to the unlabeled fractions of pyruvate and
lactate. For example, the higher m+3 fraction in G6P seen in E4 astrocytes implicates
gluconeogenesis and could be attributed to either lactate and/or pyruvate being utilized to
generate G6P and F6P, or contributions from non-oxidative PPP products. Future studies
such as astrocyte-neuron cocultures to elucidate cell-to-cell metabolic interactions, the
effect of insulin signaling on glucose flux, in vivo tracer studies in human APOE mice, and
13

C-tracer analyses in isogenic human APOE iPSCs may help to address some of these

limitations and provide additional insight into the effects of APOE on cerebral metabolism
and its ultimate relevance to the pathophysiology of AD.

3.6

Conclusion
APOE genotype is differentially modulating glucose metabolism in astrocytes. E2

and E3 have an increased flux through early glycolysis and are utilizing carbon for
oxidative metabolism in the TCA cycle. E4 astrocytes have a more active cataplerotic TCA
cycle, and increased glucose flux into lactate as well as into the PPP, which may ultimately
fuel biosynthesis pathways. Additionally, E4 has increased de novo glutathione synthesis,
which may drive the alterations in both PPP and TCA cycle.

77

Figure 3.1 APOE alters glucose metabolism in human APOE mice.
A-B) Total 13C enrichment across pyruvate (A) and lactate (B) was highest in E4 mice.
C-I) Fractional distribution pattern of 13C enrichment from glucose is shown for citrate
(C), malate (D), fumarate (E), aspartate (F), glutamate (G), γ-aminobutyric acid (GABA;
H), and pyroglutamic acid (I). Data analyzed by multiple t-tests. Values represent mean ±
SEM (n = 5-9). * p < 0.05; ** p < 0.01; *** p < 0.001.
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Figure 3.2 Experimental design, plasma glucose labeling and 13C pathway distribution
analysis after oral gavage of [U-13C] glucose.
A) Stable Isotope Resolved Metabolomics Experimental design. Immortalized astrocytes
expressing human E2, E3 or E4 were cultured for 24 hours in glucose-free media
supplemented with 10 mM [U-13C] glucose tracer. Polar metabolites were extracted from
the cells and 13C distribution among >100 metabolites was determined via ICMS (please
see Methods for details). B) Example description of fractional labeling. Fractional
enrichment of a metabolite is the abundance of an individual isotopologue (number of 13C
atoms present) divided by the sum of all isotopologues for that metabolite. The distribution
of labeling can indicate flux through a particular pathway or highlight contributions from
specific enzymes based on the labeling pattern observed. Figure adapted from Buescher et
al., 2015 [185].
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Figure 3.3 APOE affects astrocyte glucose uptake.
A) E2 astrocytes take up more glucose, while E4 astrocytes take up less glucose, relative
to E3. Immortalized astrocytes expressing human APOE were treated with 3H-2deoxyglucose (5.6 µCi/mL) in vitro and uptake was measured by a scintillation proximity
assay (SPA) over 120 min. Total area under the curve (AUC) was determined. Values
represent mean ± SEM (n = 3). Data analyzed by two-way ANOVA of repeated measures
(SPA) or t-test (AUC). *** p < 0.001.
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Figure 3.4 APOE alters glucose flux through glycolysis and the pentose phosphate
pathway.
A) Tracing of glucose carbon through glycolysis, pentose phosphate pathway (PPP), and
gluconeogenesis in astrocytes expressing E2, E3 or E4 grown in glucose tracer
supplemented media for 24 hr. Carbons are color coded based on the pathway and/or
enzyme the carbon was provided from (Grey circles: 13C; light purple: 13C from xyulose5-phospahte (X5P); dark purple: 13C from ribose-5-phosphate (R5P); white circle: nonlabeled 12C.). B-H) Fractional enrichments in the isotopologues of glucose-6-phosphate
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(G6P), fructose-6-phosphate (F6P), R5P, lactate, pyruvate, glyceraldehyde-3-phosphate
(G3P), and erythrose-4-phosphate (E4P). Not all possible labeled metabolites are shown.
The x-axis denotes percentage of total isotopic distribution per isotopologue shown. Data
analyzed by multiple t-tests. Values represent mean ± SEM (n = 3). * p < 0.05; ** p < 0.01;
*** p < 0.001.
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Figure 3.5 Alterations in glucose utilization in the TCA cycle and associated enzyme
with APOE genotype.
A) Decreased activity of TCA cycle entry enzymes pyruvate dehydrogenase (PDH) and
pyruvate carboxylase (PC) Relative enzyme activity of PDH and PC; ratio of PC/PDH (PC
enzyme activity is estimated based on the ratio of m+3 citrate relative to m+3 pyruvate.
PDH enzyme activity is estimated based on the ratio of m+2 citrate relative to m+3
pyruvate). B) Increased PC/PDH ratio mRNA gene expression. Gene expression of PC
mRNA as percentage of E3. C) Isotopic distribution pattern reveals greater incorporation
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of glucose-derived carbon into TCA cycle in E4, relative to E2 or E3. The average isotopic
distribution of TCA cycle intermediates (shown individually in E-L). D) Glucose-derived
carbon tracing through TCA cycle. Not all possible labeled metabolites are shown. Carbons
are color coded based on the pathway and/or enzyme the carbon was provided from (Grey
circles: 13C; yellow: 13C from PC; green circles: 13C from PDH; white circle: non-labeled
12
C; black outlined circles: first round of TCA; grey outlined circles: second round of
TCA). E-L) Fractional enrichments in the isotopologues of aspartate, citrate, malate,
isocitrate, fumarate, succinate, alpha-ketoglutarate, and glutamate highlighting differences
among APOE isoforms. The x-axis denotes isotopic distribution per isotopologue shown.
Data analyzed by t-test (PDH and PC) and multiple t-tests (fractional enrichment). Values
shown are mean ± SEM (n = 3). * p < 0.05; ** p < 0.01; *** p < 0.001.
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Figure 3.6 E4 astrocytes show increased de novo synthesis of nucleotides from of
glucose-derived carbon.
A-C) Comparison of total labeled isotopologues (m+1 + m+2 + … m+n) and unlabeled
(m+0) of GMP, IMP and AMP. The y-axis denotes relative abundance of each purine
phosphate normalized to cell amount (protein). D-E) Fractional enrichment of (D) purine
phosphates (AMP, ADP, ATP, GMP, GDP, GTP) and (E) uridine phosphates (UMP, UDP,
UTP) highlighting structural components attributable to isotopic distribution. Purple and
blue “clouds” denote contributions of various carbon positions to isotopologues shown (ex.
purple, pentose ring). The x-axis denotes the percentage of total 13C distribution for each
m+n fraction (select isotopologues shown). Data analyzed by multiple t-tests. Values
shown are mean ± SEM (n = 3). * p < 0.05; ** p < 0.01; *** p < 0.001.
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Figure 3.7 Increased de novo biosynthesis of glutathione, NADH, phospholipids, and
UDP-hexoses biosynthesis in E4 astrocytes.
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A) Fractional enrichment of selected isotopologues of glutathione highlighting structural
components attributable to isotopic distribution. Red, blue, or green outline denotes
contributions of carbon positions to isotopologues shown. B-C) Fractional enrichment of
(C) Glycerophosphocholine and (D) Glycerylphosphorylethanolamine D) Total 13Clabeled NADH. The y-axis denotes total NADH containing at least one 13C atom (sum of
m+1, m+2 … m+10). E) Fractional enrichment of selected isotopologues of NADH
highlighting structural components attributable to isotopic distribution. Blue and purple
outlines denote contributions of carbon positions to isotopologues shown.
F) Average fractional enrichment of selected isotopologues of UDP-hexoses (UDPglucose, UDP-galactose, UDP-N-acetylglucose, and UDP-N-acetylgalactose highlighting
structural components attributable to isotopic distribution. Blue and purple outlines denote
contributions of carbon positions to isotopologues shown. The x-axes denote percentage of
total isotopic distribution per isotopologue shown. Data analyzed by multiple t-tests.
Values shown are mean ± SEM (n = 3). * p < 0.05; *** p < 0.001.
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CHAPTER 4. METABOLIC AND TRANSCRIPTIONAL CHANGES OF THE
INFLAMMATORY RESPONSE IN ASTROCYTES ARE APOE-DEPENDENT
4.1

Prologue
The metabolic phenotype I observed in E4 astrocytes began to resemble the

metabolic profile emerging from the developing literature regarding reactive astrocytes.
Specifically, this includes increased glucose-derived lactate production and increased
glucose utilization in the PPP to sustain glutathione for oxidative stress management [98].
Not only did our data from E4 astrocytes show higher glucose flux into lactate and the PPP,
but there was also evidence of higher de novo synthesis of glutathione, amino acids, lipid
precursors, and nucleotides—all of which are upregulated during astrocyte reactivity/proinflammatory conditions. Therefore, I developed the hypothesis that E4 astrocytes under
normal conditions are pro-inflammatory and inclined toward a state of semi-reactivity,
which would be reflected by decreased metabolic and transcriptional changes after
inflammatory stimulation.
ABSTRACT
Astrocytes play an important role in regulating inflammation and metabolism in the
CNS and are also the main source of Apolipoprotein E (APOE) in the brain. Recent work
suggests astrocyte reactivity could be a major contributing factor in the development of
Alzheimer’s disease (AD). However, relatively few studies have investigated how APOE
genotype influences astrocyte immunometabolism. Thus, in the current study,
immortalized astrocytes or primary mixed glia from human APOE targeted-replacement
mice, homozygous for either E3 or E4 were acutely stimulated with a pro-inflammatory
cocktail consisting of IL-1α, TNFα, and C1q. Here we investigate the metabolic and
transcriptomic changes in immortalized astrocytes using Seahorse Glycolytic Rate Assay
88

and Mito Stress Test, steady state metabolomics, and NanoString gene expression arrays.
Additionally, metabolism was measured in mixed glial cultures via stable isotope tracer
metabolomics using a [U-13C] glucose tracer. Our findings demonstrate that both basally
and following acute inflammatory exposure, E4 expression astrocytes have altered
glycolytic function, disrupted metabolic responses, and blunted inflammatory gene
expression compared to E3 astrocytes. E3 astrocytes had a proportionally greater number
of differentially expressed genes involved in neuroinflammation and alterations in central
carbon metabolic pathways, with specific increases in adenine phosphates, lactate, and
malate. Conversely, E4 astrocytes had a lesser degree of response in both gene expression
and metabolism, with specific decreases in pantothenic acid, valine, and nacetyltryptophan. We demonstrate that E4 confers a diminished capacity for
immunometabolic reactivity of astrocytes when exposed to an acute inflammatory insult.
These findings begin to shed light on the cell type specific effects of APOE on
neuroinflammation, which is crucial for understanding E4-mediated progression of AD to
direct future studies investigating potential therapeutics for E4 carriers.

4.2

Introduction
Astrocytes are critical mediators in maintaining CNS homeostasis through a variety

of mechanisms, contributing to the viability and proper function of the blood brain barrier,
maintaining neuronal health, and oxidative stress management, to name a few. However,
during neurodegenerative inflammatory disease settings such as Alzheimer’s disease (AD),
astrocytes can acquire complex reactive states that have been shown to adversely drive
dysfunctional outcomes [91, 99, 279, 280]. These ‘disease associated’ neuroinflammatory
responses encompass a vast multicellular reactionary process in response to noxious
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stimuli. Interestingly, the extent of astrocyte reactivity correlates with cognitive decline,
occurs with the onset of AD and frequently precedes the classical AD pathological
hallmarks of amyloid and tau deposition [91, 281]. However, the consensus unfolding from
the last decade of research suggests astrocyte reactivity exhibits both maladaptive and
neuroprotective roles [282-284]. Thus, deciphering astrocyte reactivity along the timeline
of AD pathogenesis, and in relation to known AD risk factors, is critical to better
understanding this devastating disease.
The apolipoprotein E (APOE) gene encodes for three main isoforms in humans (E2,
E3, and E4). APOE is the strongest genetic risk factor for late-onset AD, where possession
of E4 confers up to a 15-fold higher risk while decreasing the age of onset up to eight years
per copy. Although a direct causative association between E4 and AD risk remains unclear,
E4 has putatively negative effects on neuroinflammation relative to E2 or E3, which likely
contributes to the progression and severity of AD [89]. Immune responses in astrocytes
and microglia are differentially regulated by APOE isoforms, with E4 eliciting the
strongest immune response and conferring greater susceptibility to neurodegeneration
associated with inflammation in mouse models expressing human APOE isoforms [93,
285, 286].
Much of the work investigating neuroinflammatory effects on metabolism have
predominately focused on microglia, although a handful of studies have examined
astrocytes specifically. Several studies suggest astrocyte reactivity increases glycolysis
while decreasing mitochondrial oxygen consumption [287-289]. Unfortunately, the
relatively few number of studies lack a consensus on metabolic effects with astrocyte
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reactivity. Furthermore, it remains unclear how APOE status might influence the metabolic
response to inflammation in astrocytes.
In the current study, we employed a multi-omics approach to examine whether
APOE isoforms affect alterations in astrocyte reactivity following an acute proinflammatory challenge. We elicited astrocyte reactivity in vitro by stimulating astrocytes
expressing either E3 or E4 with a combination of previously established inflammatory
mediators (IL1α, C1q, and TNFα) that are specifically linked to microglia-astrocyte
crosstalk [95, 99]. In this reduced model system, our data demonstrate that compared to
astrocytes expressing APOE3, APOE4 shows alterations in glycolysis and in several
metabolic intermediates associated with TCA cycle, as well as alterations in a variety of
genes associated with inflammatory response, all of which were observed in during both
basal and pro-inflammatory conditions. Cumulatively, our findings point toward APOE4
expressing astrocytes being hindered or unable to fully initiate the normal repertoire of
physiological immunometabolic mechanisms associated with mounting a response to acute
inflammatory conditions.

4.3

Materials and methods
4.3.1

Cell culture

Immortalized astrocytes derived from human APOE targeted-replacement mice,
homozygous for either E3, or E4 (kind gift from Dr. David Holtzman) [232]. Astrocytes
were maintained in Advanced Dulbecco's Modified Eagle Media (DMEM; Gibco)
supplemented with 10% FBS (VWR), 4% sodium pyruvate (Gibco) and 1% Geneticin®
(Thermo Fisher Scientific) and incubated at 5% CO2 and 37°C. For metabolomics
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experiments, cells were seeded onto tissue culture treated 6-well plates at a density of 6x105
cells/well. Approximately 24 hours later, maintenance media was replaced with either stim
media [consisting of maintenance media and the following cytokines dissolved in sterile
PBS (VWR): IL-1α (3 ng/ml; Sigma-Aldrich); TNFα (30 ng/ml;

Cell Signaling

Technology); and C1q (400 ng/ml; MyBioSource) or control media (consisting of
maintenance media and sterile PBS of equivalent volume to amount used for cytokines in
stim media) and returned to incubator. Four hours following the media change (stim or
control), polar metabolites were extracted for GCMS analysis, described below. For
NanoString gene expression assays, cells were seeded onto tissue culture treated 48-well
plates at a density of 3x104 cells/well. Approximately 24 hr later, maintenance media was
replaced with either stim media or control media, as above, and returned to incubator for 4
hr. RNA was then harvested by aspirating media and adding 350 µl of RLT Plus Buffer
(Qiagen) + 1% β-mercaptoethanol (Sigma-Aldrich) to each well to lyse the cells in
preparation for RNA harvest.

4.3.2

Primary mixed glial cell isolations

Primary astrocytes and microglia were isolated as previously described [290], from
mice (n = 6 per genotype) expressing human APOE targeted-replacement mice
(homozygous E3 or E4), taken at P0-P3 days old and the brain was isolated. After removing
the cerebellum and olfactory bulbs, the brain was transferred to ice cold dissection buffer
[Hanks Balanced Salt Solution (HBSS; Gibco), 1% HEPES (Alfa Aesar), 1% sodium
pyruvate (Thermo Fisher Scientific)]. The meninges were removed, and brains then
transferred to petri dishes containing growth media [DMEM-F12 (Gibco) containing 10%
FBS, 1% Penicillin-Streptomycin (Thermo Fisher Scientific)] and placed on ice. After
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brains were isolated, tissues were finely minced and transferred to 15 ml conical tubes on
ice. Growth media was replaced with 3 ml of trypsin-EDTA (0.25%; Thermo Fisher
Scientific) and 20 µl of TURBO DNase (Thermo Fisher Scientific), and incubated in 37 °C
water bath for 25 min, gently mixed every 5 min. Growth media was added (3 ml) to
neutralize trypsin and tubes were centrifuged at 300 x g for 5 min. Supernatant removed
and tissues were washed three times with 2 ml of HBSS. Tissue was then triturated in 10
ml of growth media and filtered through 70 µm cell strainer (VWR). After adding growth
media for a final volume of 10 ml, solution was placed in a T75 flask (USA Scientific) and
incubated at 5% CO2 and 37 °C. After 24 hr, growth media was replaced and subsequently
every 2-3 days. Twelve days post-dissection, flasks were shaken at 250 rpm for 2 hr in
incubator (5% CO2, 37°C) and media containing microglia was removed. Growth media
was then added to flasks and shaken at 250 rpm for 24 hr to remove oligodendrocyte
progenitor cells. Then 5 ml of stim or control media [containing glucose-free DMEM
(Gibco), 5% dialyzed FBS (Gibco), IL-1α (3 ng/ml), TNFα (30 ng/ ml), and C1q (400
ng/ml) for cytokine media or PBS of equivalent volume for control] was added to each
flask then returned to incubator. After 4 hr, flasks were washed with warm 0.9% NaCl to
remove non-13C glucose media and tracer media [containing glucose-free DMEM, 10mM
C glucose (Cambridge Isotopes), 5% dialyzed FBS, IL-1α (3 ng/ml), TNFα (30 ng/ ml),
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and C1q (400 ng/ml) for cytokine media or PBS of equivalent volume for control] was
added, returned to incubator for 30 min followed by polar metabolite extraction described
below.
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4.3.3

Glycolytic rate and mitochondrial respiration

The Seahorse XF96 Glycolytic Rate Assay and Mitochondrial Stress Test (Agilent)
were performed on E3 and E4 immortalized astrocytes to measure glycolysis and
mitochondrial respiration, respectively. Cells were seeded onto Seahorse XF96 Tissue
Culture Microplates (Agilent) at a density of 4x104 cells/well in maintenance media
(detailed above) and incubated at and 24 hr later maintenance media was removed, cells
washed with PBS and replaced with stim media [consisting of maintenance media, IL-1α
(3 ng/ml), TNFα (30 ng/ml), and C1q (400 ng/ml)] or control media (maintenance media
and PBS of equivalent volume to cytokine solutions) and returned to incubator for 4 hr.
After which, Glycolytic Rate Assay and Mitochondrial Stress Test were performed
according to manufacturer’s instructions.
For Glycolytic Rate Assay, stim or control media was replaced with glycolytic rate
assay medium (DMEM-based, consisting of 10 mM glucose, 2 mM glutamine, 1 mM
pyruvate, pH 7.4) and incubated at 5% CO2 and 37°C for 1 hr before assay. Plate was
measured under basal conditions followed by serial addition of (A) rotenone and antimycin
A (0.5 µM) and (B) 2-deoxyglucose (50 mM).
For Mitochondrial Stress Test, stim or control media was replaced with
mitochondrial stress test assay medium (XF base medium, consisting of 10 mM glucose, 2
mM glutamine, 1 mM pyruvate, pH 7.4) and incubated at 5% CO2 and 37°C for 1 hr before
assay. Plate was measured under basal conditions followed by serial addition of (A)
oligomycin (1 µM), (B) FCCP (0.6 µM), and (C) rotenone and antimycin A (0.5 µM).
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4.3.4

Gene expression

RNA was isolated using RNeasy Plus kit following manufacturer’s suggested
protocol (Qiagen). Quality and concentration of eluted RNA was measured by Nanodrop
spectrophotometer. Approximately 50 ng of total RNA per sample (n = 3 wells/condition)
was quantified using a NanoString array that consisted of 757 gene targets (Mouse
Neuroinflammation v1 CodeSet). Following quality control, assay background subtraction
(geometric mean of negative control values), and housekeeping normalization, there were
a total of 453 genes examined across all samples. Raw RNA counts were analyzed for
differential expression using NanoString’s analysis software (nSolver 3.0). For the purpose
of this experiment we considered only genes that showed at least a 2-fold change
biologically relevant, following FDR-adjusted (Benjamini, Krieger and Yekutieli) multiple
comparisons correction.

4.3.5

Sample preparation for GCMS analysis

Immediately following the last incubatory period of each experiment, plates were
removed from the incubator and placed on crushed dry ice, the media was removed, cells
were washed twice with ice cold 0.9% NaCl, then 1 ml of ice cold 50% MeOH (HPLCgrade; Sigma-Aldrich) containing 20 µM L-norleucine (Sigma-Aldrich) was added to
quench cellular metabolic activity followed by 10 min incubation at -80 °C to ensure cell
lysis. After removing from the freezer, plates were placed on ice, wells scraped with a cell
scraper and the entire contents collected into a tube, vortexed briefly and placed on ice until
all samples were collected. The tubes were then placed on a Disruptor Genie Cell Disruptor
Homogenizer (Scientific Industries) for 5 min at 3,000 rpm. Tubes were then centrifuged
at 24,000 x g for 10 min at 4 °C. The aqueous fraction was isolated to a new tube for further
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processing, the resulting pellet was briefly dried at 10-3 mbar using a SpeedVac to evaporate
remaining MeOH followed by determination of protein content via BCA Protein Assay Kit
(Pierce; Thermo Fisher Scientific). The aqueous fraction containing polar metabolites was
dried at 10-3 mbar followed by derivatization. The dried polar metabolite pellet was
derivatized by a two-step methoxyamine protocol first by addition of 50 µl methoxyamine
HCl (Sigma-Aldrich) in pyridine (20 mg/ml; Sigma-Aldrich) followed by 90 min dry heat
incubation at 30 °C. Samples were then transferred to amber V-shaped glass
chromatography vials (Agilent) and sequential addition 80 µl N-methyl-trimethylsilyltrifluoroacetamide (MSTFA; ThermoFisher Scientific) followed by 30 min dry heat
incubation at 37 °C. The samples were allowed to cool to room temperature then analyzed
via GCMS.

4.3.6

GCMS quantification

GCMS (Agilent) protocols were similar to those described previously [175] except a
modified temperature gradient was used for GC: Initial temperature was 130°C, held for 4
min, rising at 6°C/min to 243°C, rising at 60 °C/min to 280 °C, held for 2 min. The electron
ionization (EI) energy was set to 70 eV. Scan (m/z: 50–800) and full scan mode were used
for metabolomics analysis. Mass spectra were translated to relative metabolite abundance
using the Automated Mass Spectral Deconvolution and Identification System (AMDIS)
software matched to the FiehnLib metabolomics library (available through Agilent) for
retention time and fragmentation pattern matching with a confidence score of >80 [158,
178]. Quantitation was performed and corrected for natural abundance using the Data
Extraction for Stable Isotope-labelled metabolites (DExSI) with a primary ion and at least
2 or more matching qualifying ions. Relative abundance was corrected for recovery using
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L-norvaline and adjusted to protein input from BCA measure to correct for any differences
in tissue quantity used for extraction.

4.3.7 Metabolomics data analysis
For volcano plot, fold-enrichment and pathway impact analyses, the online tool
Metaboanalyst was used. For pathway impact analysis, data were filtered using
interquartile range (IQR) function and scaled using auto-scaling, in which mean-centered
values were divided by the standard deviation of each variable. Global test’ and ‘Relative
Betweenness Centrality’ parameters were used to determine metabolic pathway ‘hub’
importance. For 13C tracer experiments, fractional enrichment was calculated as the relative
abundance of each isotopologue relative to the sum of all other isotopologues.

4.3.8

Statistical analysis

All data are expressed as mean values ± standard error. Comparisons between two
groups were analyzed by unpaired, two-tailed t-test or multiple unpaired, two-tailed t-tests
(one per row) for comparisons with multiple isotopologues. Statistical significance was
determined using an error probability level of p < 0.05 corrected using the two-stage linear
step-up procedure of Benjamini, Krieger and Yekutieli, with Q = 1%. Statistical details can
be found in figure legends for each figure, all statistical analyses were calculated using
GraphPad Prism 8.
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4.4
4.4.1

Results
E3 astrocytes increase glycolytic rate following pro-inflammatory stimulation
Our previous work has demonstrated E4-expressing astrocytes have altered

glycolytic utilization of glucose under normal conditions. To test the metabolic response
to inflammatory stimuli in astrocytes based on APOE genotype, we exposed E3 and E4
astrocytes to three canonical inflammatory cytokines—IL1α, C1q, and TNFα. We first
performed functional measures of glycolysis and oxidative phosphorylation using
established Seahorse assays. First, E3 and E4-expressing immortalized astrocytes were
treated with the stimuli for 4 hours and analyzed for proton efflux rate (PER) using the
Seahorse Glycolytic Rate Assay (Fig. 4.1A). There was a significant interaction among
genotype and treatment in basal glycolysis with E3 stim significantly higher than E3
controls, while no effect was observed among E4 stim versus controls (Fig. 4.1B). A
significant interaction by genotype was also observed in compensatory glycolysis, with E3
astrocytes showing an increase in glycolysis following the inflammatory stimuli, however,
no effect was observed among E4 astrocytes (Fig. 4.1C). These results are consistent with
recent findings from primary astrocytes isolated from humanized E3 and E4 mice, where
E4 astrocytes had a higher glycolytic rate [291]. Cells were also analyzed for oxygen
consumption rate (OCR) using the Seahorse Mito Stress Test (Fig. 4.1D). Similar to
previous findings [291], E4 astrocytes displayed a lower OCR compared to E3 astrocytes,
but there was no significant effect of the inflammatory stimuli on oxygen consumption in
either genotype (Fig. 4.1D-F).
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4.4.2

E3 and E4 differentially affect metabolism in astrocytes
To establish baseline differences in metabolism (prior to exposure to the

inflammatory stimuli), we first conducted a targeted metabolomics analysis of E3 and E4
astrocytes at rest. A pathway enrichment analysis comparing metabolic differences among
E3 astrocytes to E4 astrocytes scores pathways based on changes among metabolites within
each pathway and showed a total of 13 pathways that were significantly different between
E3 and E4 astrocytes (Figure 4.2A). Of the pathways most significantly altered between
E3 and E4 astrocytes, the “valine, leucine, and isoleucine degradation” pathway had the
greatest degree of change and was the most significantly enriched pathway, while the
“TCA cycle”, “glycolysis”, and “pyruvate metabolism” were also among the top five most
significantly enriched pathways between unstimulated E3 and E4 astrocytes (Figure 4.2A).
We next performed a pathway impact analysis, which is a multi-dimensional analysis
that incorporates pathway enrichment and betweenness centrality (the number of
connecting paths to a given metabolite), to provide a pathway impact score. Altogether,
there were 14 pathways significantly different between E3 and E4 astrocytes, with the
following top hits: “pantothenate and CoA metabolism”, “TCA cycle”, “pyruvate
metabolism”, “glycine, serine, and threonine metabolism”, and “β-alanine metabolism”
(Figure 4.2B). Comparing the fold change of each individual metabolite detected in our
targeted analysis, 13 of 14 significantly different metabolites had higher concentrations in
E4 astrocytes compared to E3 (Figure 4.2C). Three glycolysis intermediates were increased
in E4 astrocytes: pyruvate, lactate, and fructose-6-phosphate (F6P) (Figure 4.2C).
Fumarate and eight amino acids were present in higher concentrations in E4 astrocytes
(leucine, serine, valine, glutamine, threonine, methionine, N-acetyltryptophan; NAT, and
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pyroglutamate; PG), while the amino acid β-alanine is the only metabolite detected that
was significantly higher in E3 relative to E4 (Figure 4.2C-E). Together, these findings
indicate differences in astrocyte metabolism associated with APOE genotype, largely
attributed to changes in amino acid pathways and central carbon metabolism (glycolysis,
TCA cycle, and pyruvate metabolism).

4.4.3

E3 astrocytes demonstrate a greater metabolic response to inflammation
Having established the baseline differences between E3 and E4 astrocytes, we next

looked for changes in the E3 or E4 astrocyte metabolome following inflammatory
stimulation. The inflammatory cocktail elicited 1.7-fold increase in adenine-phosphates
(AXP) in E3 astrocytes relative to their non-stimulated controls, while also increasing
lactate and malate to a lesser degree (Figure 4.3A,B). E4 astrocytes showed a different, and
relatively muted, response where N-acetyltryptophan (NAT), valine, and pantothenic acid
were all decreased, ranging from 1.5- and 1.6-fold lower in stimulated E4 astrocytes
compared to E4 controls (Figure 4.3C,D). A pathway enrichment analysis in E3 astrocytes
showed purine metabolism, pyruvate metabolism, and glycolysis were significantly altered
when comparing E3 stimulated astrocytes to controls (Figure 4.3E). In contrast,
inflammatory stimulation in E4 astrocytes did not elicit any significant differences in
metabolic pathways when compared to non-treated controls (Figure 4.3F). These findings
suggest E3 astrocytes exhibit a more robust metabolic response to inflammation, with
major alterations in purine metabolism and central carbon metabolism. Conversely,
inflammation in E4 astrocytes resulted in a muted response, with slight decreases in
pantothenic acid, and the amino acids valine and NAT, and most notably no significant
pathway level alterations.
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4.4.4

APOE genotype drives a variety of metabolic changes in astrocytes following
pro-inflammatory stimulation
We next examined the effect of APOE within astrocytes treated with the

proinflammatory stimuli (E3 stimulated vs E4 stimulated). A pathway enrichment analysis
identified six metabolic pathways, highlighting the “TCA cycle” as the pathway most
significantly altered by APOE (Figure 4.4A). Further, a pathway impact analysis of
stimulated E3 and E4 astrocytes highlighted the following pathways: glycine, serine, and
threonine metabolism; glyoxylate and dicarboxylate metabolism; and the TCA cycle
(Figure 4.4B). An analysis of individual metabolite concentrations showed 11 metabolites
as higher in E3 stimulated astrocytes relative to E4 with a 2-fold increase in the following
four metabolites: dihydroxyacetone phosphate, dihydroxyacetone, α-ketoglutarate, and
citrate (Figure 4.4C-E). Conversely, three metabolites were significantly increased in E4
stimulated astrocytes: F6P was 3-fold higher, aspartate, and glutamine were between 1.5and 2-fold higher relative to E3 stimulated astrocytes (Figure 4.4C-E).

4.4.5

Mixed glial cultures show altered glucose flux after inflammatory stimulation
Given the metabolic differences we observed in E3 and E4 astrocytes, notably in

glycolysis and the TCA cycle, we next sought to examine glucose metabolism more
specifically in a co-culture setting that captures the dynamic interactions between glial cells
in the brain. Using [U-13C] glucose in mixed glial cultures (consisting of astrocytes and
microglia) we measured downstream metabolism of glucose in primary cultures isolated
from mice expressing either human E3 or E4 (Figure 4.5A). We did not observe a
significant effect of either treatment or genotype on
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C enrichment from glucose into

pyruvate nor lactate (Figure 4.5B,C). However, there was an overall effect of the
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inflammatory stimulus in glucose incorporation into the TCA cycle, as both E3 and E4
stimulated astrocytes showed increased TCA intermediate labeling compared to their
respective controls. Further, we did not observe a significant effect based on APOE
genotype (Figure 4.5D).

4.4.6

E3 astrocytes display more robust changes in gene expression of inflammatoryrelated pathways in response to inflammatory stimulation
To further understand how the APOE isoforms influence astrocyte reactivity, we next

measured mRNA expression of over 450 genes in E3 and E4 astrocytes using the
Nanostring neuroinflammation panel. Genes that were differentially expressed among each
comparison of genotype and/or treatment were analyzed against gene sets that share a
common biological function identified by gene ontology and scored based on overlap.
We first compared E4 controls against E3 controls to establish how the APOE
isoforms may differ in expression of genes involved in neuroinflammation at baseline
(Figure 4.6A). We found 111 genes in total were significantly different between E3 and E4
astrocytes at baseline, with 75 genes upregulated in E3 and 36 genes upregulated in E4
(Figure 4.6A, left). The gene enrichment analysis between E3 and E4 control groups had
the lowest overall enrichment scores relative to other comparisons (Figure 4.6A, right). To
understand the specific effects of E3 and E4 in response to inflammatory mediators, we
compared stimulated E3 astrocytes to E3 controls and stimulated E4 astrocytes to E4
controls (Figure 4.6B,C). E3 astrocytes differentially expressed 52 genes in response to
inflammatory stimuli, 41 of which were upregulated and 11 downregulated relative to E3
controls (Figure 4.6B, left). We observed a lesser degree of response in E4 with only 33
genes differentially expressed, 31 of which were upregulated in stimulated E4 astrocytes
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relative to controls while only one gene, Osgin1, was downregulated (Figure 4.6C, left).
We observed little overlap among gene pathway analysis results in E3 and E4 stimulated
astrocytes relative to their respective controls and notably lesser scores in E3 relative to E4
(Figure 4.6B,C, right) Comparing stimulated E4 astrocytes with stimulated E3 astrocytes
revealed 126 differentially expressed genes, 33 of which upregulated in E4 (or
downregulated in E3) and 93 upregulated in E3 (or downregulated in E4) (Figure 4.6D,
left). Gene pathway enrichment analysis comparing E4 and E3 stimulated groups (Figure
4.6D, right) showed a similar set of pathways to the results obtained from the E4 stim
versus controls. Interestingly, cytokine-mediated signaling pathway was the most
significant gene set identified across all four comparisons of genotype and treatment
(Figure 4.6A-D, right). Altogether, E3 astrocytes exhibited a greater number of changes in
gene expression in response to the inflammatory stimuli while E4 astrocytes exhibited
greater overlap, evidenced by higher enrichment scores. Furthermore, these data indicate
there are differences between E3 and E4 astrocytes in gene expression of inflammatory
pathways at baseline which are exacerbated with the induction of inflammation via proinflammatory cytokines.
A four-way Venn diagram highlights differentially expressed genes, either
upregulated or downregulated, based on treatment and genotype while also showing the
number of genes that were common among various groups (Figure 4.7A,B). Differences
based on APOE genotype alone showed 14 unique genes differentially expressed (three
upregulated in E4 controls and 11 downregulated, relative to E3 controls). There were 36
genes uniquely differentially expressed between E4 and E3 following inflammatory
stimulation (five upregulated in E4 and 31 downregulated, relative to E3). We observed a
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divergent response when comparing E3 and E4 astrocytes following stim relative to their
respective controls where 17 genes were uniquely differentially expressed in E3 (12
upregulated and five downregulated), while there were only three genes unique in E4 (two
upregulated and one downregulated) (Figure 4.7A,B).
These findings suggest APOE genotype differentially modulates the transcriptional
response to inflammation, where the response in E3 is greater than that in E4 astrocytes.
Considering the results altogether, the metabolic and transcriptional response to
inflammation in E4 is less than that of E3.

4.5

Discussion
Our findings corroborate previous work showing metabolism in astrocytes is APOE-

dependent. Furthermore, our findings also indicate that metabolic pathways most effected
by APOE genotype in astrocytes after inflammatory stimuli are involved in amino acid
metabolism and the TCA cycle. In comparison of E3 and E4 controls, we observed
transcriptional differences in genes connected to inflammatory response which provides
evidence that E3 and E4 astrocytes have significant differences in neuroinflammation at
baseline. Considering the degree of transcriptional changes in response to stim in E3 were
greater than in E4, specifically in cytokine-mediated signaling and inflammatory response
pathways, suggests E3 elicits a more profound response to pro-inflammatory stimulation.
These findings provide novel insight into the transcriptional and metabolic alterations
associated with APOE genotype in reactive astrocytes.
Astrocyte reactivity, canonically determined by glial fibrillary acid protein (GFAP)
expression, describes a set of morphological, functional, and metabolic changes exhibited
by astrocytes in response to CNS insult [96, 97]. Adopting the nomenclature of designating
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astrocytes as either A1 or A2 based on certain phenotypic criteria implies explicit
boundaries, which presents difficulty when characterizing astrocytes that exhibit
characteristics of both. While it may serve useful purpose by simplifying the distinction
between reactive and non-reactive astrocytes, a refined approach is necessary to further
distinguish subpopulations of astrocytes, especially among those exhibiting various states
of reactivity. For example, Habib, et al. describes two prominent groups of astrocytes in
5xFAD mice that both fit the canonical defining characteristic of increased GFAP
expression associated with astrocyte reactivity, yet had distinct gene expression profiles
[279]. While the two groups displayed several similarly upregulated genes other than
GFAP, the group termed disease-associated astrocytes (DAAs) had increased expression
of genes associated with amyloid processing, the complement cascade, and aging. Further,
the authors discovered astrocytes of a similar profile to DAAs in human brains, which were
also more prevalent in AD brains.
Astrocyte reactivity is consistent with low grade inflammation and chronic lowgrade inflammation itself is associated with earlier onset of AD [292]. The extent of
morphological and functional changes associated with reactive astrocytes is a vastly
extensive topic that requires great detail beyond the scope of our study. We will instead
direct our focus to the metabolic and transcriptomic changes associated with inflammation
and reactivity in astrocytes.
Astrocytes play a critical metabolic role to sustain neuronal function relying
primarily on glycolysis to provide energy substrates, mainly lactate, to neurons while using
the TCA cycle to replenish neurotransmitters [205, 293, 294]. Thus, efficient astrocyte
metabolism is indispensable for optimal neuronal function and CNS health. However,
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astrocytes must also respond to inflammatory stimuli, and accumulating evidence suggests
that cellular metabolism and inflammatory responses are fundamentally linked.
A study by Bélanger et al. compared the metabolic effects of various inflammatory
cytokines in primary astrocytes and found that treatment with pro-inflammatory stimuli
increased glucose utilization, while anti-inflammatory stimuli tended to decrease glucose
utilization [295]. Intriguingly, the authors found that pro-inflammatory stimulation of
primary astrocyte-neuron co-cultures, but not primary neuron cultures alone, increased
neuronal viability in response to an excitotoxic glutamate challenge, perhaps suggesting
that metabolic changes in astrocytes after pro-inflammatory insult increases their capacity
to support neuron health. More recently, a study by Robb et al. found that LPS treatment
for 3 hours induced glycolysis in primary astrocytes, and furthermore, that levels of nuclear
factor-kappa b (NF-κB) signaling controlled basal metabolism even in the absence of LPS
treatment [296]. Thus, astrocyte metabolism and inflammatory responses are intrinsically
linked.
We previously used stable isotope resolved metabolomics with 13C-labeled glucose
to show that unstimulated E4 astrocytes have increased flux of glucose into lactate
compared to E3 astrocytes, perhaps indicative of increased basal glycolysis. In agreement
with our previous results, through using traditional, steady state metabolomics we show an
increase in the glycolytic metabolites fructose-6-phosphate (F6P), pyruvate, and lactate in
the

control

E4

astrocytes

compared

to

control

E3

astrocytes,

with

glycolysis/gluconeogenesis significantly altered in the pathway enrichment and pathway
impact analyses. This evidence for increased glycolysis in E4 astrocytes might indicate a
broader immunometabolic dysregulation, as high rates of glycolysis would typically be
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associated with pro-inflammatory phenotypes; however, E4-expressing astrocytes are
instead thought to be more anti-inflammatory than E3 astrocytes [89].
In the present study, we sought to unravel the effects of this altered metabolic
preference on the response to an inflammatory stimulus. When treated with our stimulation
cocktail (IL-1β, TNFα, and C1q), E3 astrocytes showed an increase in lactate, malate, and
adenine phosphates (AXP), which may indicate increased ATP production through
glycolysis. This finding is in accordance with the above-mentioned literature, in that proinflammatory stimulation of astrocytes is expected to induce a glycolytic shift. It was
therefore striking that E4 astrocytes did not display this shift upon stimulation, instead
decreasing levels of the metabolites N-acetyltryptophan (NAT), valine, and pantothenic
acid, while having no significant effect on lactate or other metabolites related to glycolysis.
Furthermore, pathway analysis revealed pyruvate metabolism, glycolysis, and purine
metabolism as significantly altered by the stim cocktail only in E3 astrocytes, whereas no
significant pathways were returned when the same analysis was run on E4 stim versus E4
control. These results indicate that E4 astrocytes may exhibit a lesser response to
inflammatory stimulation than E3 astrocytes, which may prove consequential in conditions
with a prominent neuroinflammatory component.

4.6

Conclusion
To determine the metabolic effects of astrocyte reactivity by APOE genotype, we

conducted a mutli-omics approach using mRNA gene expression targeted, steady-state
metabolomics analysis on E3 and E4 astrocytes (+/- stim), isolating metabolites spanning
central carbon metabolism and connecting pathways. Altogether our findings indicate E3
may be better suited and able to elicit a more profound inflammatory response, whereas E4
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astrocytes appear largely unchanged. Metabolically, E4 astrocytes appear to be in a proinflammatory state; however, if not, their lack of metabolic response might suggest they
are at least metabolically primed for an inflammatory response, thus contributing to an
altered immunometabolic phenotype in relation to E3. Utilizing a proteomics approach to
specifically quantify the levels of pro-inflammatory factors in E4 astrocytes at baseline are
necessary with further studies to conclude whether E4 astrocytes are indeed reactive at rest.
Future studies investigating the differential effects of APOE on astrocyte and glia
activation may elucidate targets to mitigate neuroinflammation that would decrease AD
risk associated with E4, reduce the severity of AD progression, or even prolong disease
onset.
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Figure 4.1 Glycolytic rate, but not mitochondrial respiration, is APOE-dependent in
response to inflammation.
A) Proton extrusion rate (PER), a measure of glycolysis (lactate production), was
determined using the Seahorse XF Cell Glycolytic Rate Assay Kit (Agilent). B-C) Both
basal rate and compensatory glycolysis (measured after mitochondrial inhibition) increased
in E3 astrocytes, but not E4, following addition of inflammatory stimuli. We observed a
genotype effect for both basal glycolysis (B) and compensatory glycolysis (C), while a
significant effect of inflammatory stimulus only in E3 astrocytes.
D-F) Oxygen consumption rate (OCR), a measure of mitochondrial oxidative
phosphorylation, was determined using the Seahorse XF Cell Mito Stress Test Kit
(Agilent). We observed a significant effect based on APOE genotype for basal respiration
(E) and maximal respiration (F) but no significant effect of treatment in either E3 or E4
astrocytes. Data analyzed by two-way ANOVA with Sidak’s multiple comparisons
correction (B,C,E,F). Values represent mean ± SEM (n = 6 per group). * p < 0.05, **** p
< 0.001).
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Figure 4.2 Metabolic differences between E3 and E4 astrocytes at baseline.
A) Pathway enrichment analysis compares the primary metabolic pathways differing
between non-stimulated E4 astrocytes (E4 control) and non-stimulated E3 astrocytes (E3
control). B) Pathway impact analysis among E4 and E3 controls describes changes in
metabolic networks using a multi-dimensional illustration of metabolic pathways based on
pathway enrichment and topological analysis (x-axis), pathway coverage (dot size), and
statistical significance (y-axis). Dots numbered for identification purposes, not based on
impact score or significance. C) Volcano plot shows fold change of metabolites detected
with statistically significant metabolites (p <0.05) highlighted in color. D,E) Scatter dot
plots further highlight differences among significantly altered metabolites identified by
fold change comparison in panel C. (F6P, fructose-6-phosphate; β-Ala, β-alanine; PG,
pyroglutamate; NAT, N-acetyltryptophan). Data analyzed by unpaired t-test (D,E). Values
represent mean or mean ± SEM (n = 3). * p < 0.05; ** p < 0.01; *** p < 0.001.
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Figure 4.3 Effect of inflammatory stimulation on metabolism in E3 and E4 astrocytes.
A,C) Volcano plots show fold change of metabolites detected among: (A) stimulated E3
astrocytes (E3 stim) relative to non-stimulated E3 astrocytes (E3 control); or (C) stimulated
E4 astrocytes (E4 stim) relative to non-stimulated E4 astrocytes (E4 stim). Significant
values (p <0.05) shown in color. B,D) Scatter dot plots highlight statistically significant
changes in individual metabolites identified from panel A or C among: (B) E3 stim and E3
control; or (D) E4 stim and E4 control.. E,F) Pathway enrichment analysis shows the major
metabolic pathways differing between either: (E) E3 stim and E3 control; or (F) E4 stim
and E4 control. [AXP; adenine phosphates (mono-, di-, tri-); NAT, N-acetyltryptophan]
Data analyzed by unpaired t-test (B,D). Values represent mean or mean ± SEM (n = 3). *
p < 0.05; ** p < 0.01; *** p < 0.001.
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Figure 4.4 Metabolic differences between E3 and E4 astrocytes after inflammatory
stimulation.
A) Pathway enrichment analysis shows the metabolic pathways most different between
stimulated E4 astrocytes (E4 stim) and stimulated E3 astrocytes (E3 stim). B) Pathway
impact analysis of E4 stim and E3 stim provides a multi-dimensional illustration of
metabolic pathways based on pathway enrichment and topological analysis (x-axis),
pathway coverage (dot size), and statistical significance (y-axis). Dots numbered for
identification purposes, not based on impact score or significance. C) Volcano plot shows
fold change across metabolites in E4 stim and E3 stim. Significant values (p <0.05) shown
in color. D,E) Scatter dot plots further highlight statistically significant changes in
individual metabolites identified from panel C among E4 stim and E3 stim. [αKG, αketoglutarate; DHA, dihydroxyacetone; DHAP, dihydroxyacetone phosphate; NAN, Nacetylneuraminic acid; AXP, adenine phosphates (mono-, di-, tri-); F6P, fructose-6phosphate]. Data analyzed by unpaired t-test (D,E). Values represent mean or mean ± SEM
(n = 3). * p < 0.05; ** p < 0.01; *** p < 0.001.
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Figure 4.5 Glucose flux through the TCA cycle in glial cells is altered by inflammatory
stimulation independent of APOE.
A) Experimental design depicting [U-13C] glucose tracer in inflammatory stimulated E3
and E4 primary mixed glial cultures from human APOE targeted-replacement mice and
glucose tracing diagram highlighting glucose incorporation from glycolysis into lactate
and/or the TCA cycle. B-D) Fractional enrichment of 13C labeling in pyruvate (B), lactate
(C), and average TCA cycle intermediates (D), which showed a significant effect of
inflammatory stimulus in both E3 and E4 astrocytes but did not differ based on APOE
genotype. Data analyzed by two-way ANOVA with Sidak’s multiple comparisons
correction. Values represent mean ± SEM (n = 3). * p < 0.05.
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Figure 4.6 Effect of APOE genotype on expression of neuroinflammatory genes in
astrocytes.
Volcano plots (left) and gene ontology pathway enrichment (right) highlight differentially
expressed genes among the following pairwise comparisons: (A) non-stimulated E4
astrocytes (E4 control) relative to non-stimulated E3 astrocytes (E3 control), yellow; (B)
E3 stimulated astrocytes (E3 stim) relative to E3 control, blue; (C) E4 stimulated astrocytes
(E4 stim) relative to E4 control, orange; and (D) E4 stim relative to E3 stim, green.
Threshold criteria for differentially expressed genes determined as a fold change greater
than two (or log2(FC) >1) and q value < 0.01 (-log2(q value) >1), shown as colored dots
(genes below threshold shown as grey dots). Names of the top five genes with the greatest
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fold change in each comparison are highlighted in volcano plots. All differentially
expressed genes (upregulated and downregulated) per comparison which met threshold
criteria were cross-referenced against annotated gene sets using Enrichr (gene ontology
biological processes). Data analyzed by multiple comparisons adjusted for false discover
rate (volcano plots) and Fisher’s exact test corrected for multiple hypotheses (pathway
enrichment). Values represent mean fold change or combined score (n = 3).
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Figure 4.7 Comparison of differentially expressed genes in astrocytes by APOE
genotype and neuroinflammatory status.
A,B) Venn diagrams show the number and similarity of genes either upregulated (A) or
downregulated (B) compared by APOE genotype (E3 or E4) and inflammatory stimuli (S)
or control (C). Each circle reflects the number of differentially expressed genes per
pairwise comparison, distinguished by color: E3 stim relative to E3 control (E3S-E3C;
blue); E4 control relative to E3 control (E4C-E3C; yellow); E4 stim relative to E3 stim
(E4S-E3S; green); E4 stim relative to E4 control (E4S-E4C; red). The number of
upregulated (A) or downregulated (B) genes per comparison are shown in parentheses
above each ellipse. Values within ellipses represent the number of upregulated (A) or
downregulated (B) genes in each subsection and the percentage relative to the total number
of upregulated or downregulated genes across all groups are shown in parentheses.
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CHAPTER 5. DISCUSSION AND EXPERT OPINION

5.1

Summary of dissertation
The dissertation work contained herein describes a stable isotope tracer

metabolomics method of particular importance for in vivo studies which is leveraged to
examine the effect of APOE genotype on cerebral glucose metabolism in a humanized
mouse model expressing E2, E3, or E4 isoforms. The method effectively demonstrates
APOE as a metabolic regulator in the brain whereby glucose appropriation into late-stage
glycolysis and the TCA cycle is isoform-specific and was greatest in E4 mice. Given
astrocytes are the central hub of glucose metabolism and primary source of APOE in the
brain, I sought to understand how APOE genotype was affecting astrocytes specifically.
The results in astrocytes showed similar isoform-specific effects in central carbon
metabolism to what I observed in mice, although an intriguing pattern of glucose utilization
in glycolysis revealed a striking increase in PPP activity in E4 astrocytes. Further analysis
of downstream glucose metabolism in E4 astrocytes revealed a pattern of metabolic
regulation commonly associated with reactive astrocytes which indicated glycolytic
regulation, oxidative stress, glutathione synthesis, lipid and nucleotide biosynthesis, and
biomass production. These findings motivated a more targeted approach utilizing a
combined metabolic and transcriptomic approach to understand how APOE may influence
the immunometabolic response in astrocytes. My work concludes APOE genotype alters
glucose flux through central carbon metabolism pathways in astrocytes and is driven by a
proclivity for inflammation. However, whether metabolism is the determining factor in
inflammatory activation of E4 astrocytes is unknown.
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APOE genotype is the single greatest genetic determinant of AD risk, and as such,
its effect on classical hallmark pathologies have long been established; however, the
specific effects on cerebral glucose metabolism and neuroinflammation have not received
as much attention. Furthermore, although the immunometabolic field has recently emerged
and is quickly developing, the effects of APOE have been studied extensively in myeloid
cells but are rather limited in astrocyte-specific studies. Not only does this dissertation
work contribute to the growing body of APOE literature but also provides an advance to
the metabolomics field through a detailed protocol for stable isotope tracer studies in vivo
and offers insight into fundamental processes of AD progression.

5.2

The role of glucose metabolism in the development of Alzheimer’s disease
Cerebral glucose hypometabolism has been associated with ε4 as early as 1995, just

two years after APOE was originally identified as a genetic risk factor for AD [45, 297].
Despite nearly three decades since, a clear mechanism has yet to be established as to how
APOE isoforms differentially influence cerebral glucose metabolism. Furthermore, after
almost four decades since glucose hypometabolism was first described in AD patients, the
fundamental underlying cause of metabolic dysfunction is unknown [298, 299].
Despite a large and growing body of evidence, there is still skepticism as to whether
glucose hypometabolism is simply a result of disease progression, often arguing synaptic
loss and neuronal cell death as the primary cause [138, 300]. From the knowledge I have
acquired throughout my own research and the existing literature, and because such a belief
may oppose the work myself and many others have done, I feel it is appropriate and
necessary to address the role of astrocyte metabolism in the progression of AD.
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Although neurons do utilize glucose, their actual uptake is very limited in
comparison to astrocytes. Direct neuronal uptake of glucose without an astrocyte mediator
requires glucose to enter the brain through tight junctions of conjoining endothelial cells,
diffuse across the basal lamina in spaces between astrocytic end-feet, or through uptake
and transport by pericytes lining the blood vessels ultimately for neurons to import from
interstitial fluid. Although the former mechanisms are active in the normal brain, the
majority of glucose is likely transported by astrocytes given the direct cerebrovascular
access and high coverage of capillaries by end-feet [105, 209, 301]. While the rate of uptake
in astrocytes rapidly accelerates with brain activation, direct in vivo evidence from rats
shows astrocytes account for more than 50% of glucose cerebral uptake at rest, supporting
astrocytes as the predominate pathway by which glucose enters the brain [104, 107]. It is
therefore unlikely glucose hypometabolism is specific to neurons, especially in the early
stages of AD.
The initial cognitive decline with AD results from synaptic loss which is attributable
to amyloid and tau pathology and eventually results in neuronal death, ultimately giving
rise to worsening cognitive impairment [134, 302, 303]. Recent studies suggest a primary
role for tau in the progression of synaptic dysfunction whereby tau is necessary for
amyloid-induced toxicity [304]. Interestingly, synaptic loss correlates with cognitive
decline in AD patients and, similar to glucose hypometabolism, is a predictor of
progression from MCI to AD [305, 306]. Furthermore, the spatial propagation of tau
pathology is followed by synaptic loss which interestingly also follows a similar pattern to
the regional distribution of glucose hypometabolism in the progression of AD [307].
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Furthermore, direct in vivo evidence in mice expressing human tau showed deficient
glucose metabolism stimulated tau pathology, decreased synaptic function, and caused
memory impairments [308]. Despite long-standing debate, the metabolic coupling of
glucose utilization in astrocytes with synaptic activity has been demonstrated in vivo
through magnetic resonance imaging and is supported by in vitro evidence [309].
Substantial evidence demonstrates glucose hypometabolism predates clinical and
pathological manifestations of AD, which are a result of primarily tau-mediated synaptic
loss. In addition to the evidence establishing a link between glucose metabolism in
astrocytes and the synaptic function of neurons, there is probable argument that impaired
glucose metabolism in astrocytes contributes to tau-mediated synaptic loss and ultimately
cognitive decline.
If metabolic dysfunction in astrocytes has an underlying role in the development of
AD, many associations with E4 in disease processes would be further rationalized. E4
astrocytes exhibit decreased neurotrophic support, are less capable of promoting synapse
formation, and result in decreased synaptic protein expression and ultimately decreased
survival of neurons [310]. These deleterious features of E4 astrocytes likely promote
cognitive dysfunction, which may be exacerbated in a state of reactivity given synaptic loss
is also mediated by glial inflammation [311]. The differences in glucose metabolism this
work describes, may in sum contribute to the decrease in neurotrophic support of E4
astrocytes affecting disease processes that lead to an earlier development of pathology in
neurons which results in the increased prevalence of AD for E4 carriers.
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5.3

Evidence of metabolic dysfunction, inflammation, and oxidative stress in E4
astrocytes
Oxidative damage is the main effector by which neuroinflammation induces

detrimental effects. Reactive astrocytes undergo metabolic changes in response to
neuroinflammation that increase oxidative stress through generation of ROS, which if
unchecked results in oxidative damage. Interestingly, the extent of astrocyte reactivity
correlates with cognitive decline and much like glucose hypometabolism, presents prior to
clinical manifestations of AD and frequently precedes development of classical
pathological hallmarks [91, 281, 312].
While the exact metabolic changes that occur with astrocyte reactivity are not clearly
understood, glycolysis is directly influenced by the mechanisms astrocytes utilize to
combat the increased oxidative stress that occurs with reactivity [313]. With oxidative
damage occurring rapidly after ROS generation, the most readily available mechanism to
mitigate oxidative stress is to generate NAPDH through the PPP as it is necessary for redox
management via glutathione [135]. Upregulating the PPP in response of ROS formation
sufficiently produces NADPH allowing glutathione recycling to sustain; however, to
ensure NADPH levels are adequate, glyceraldehyde-phosphate dehydrogenase (GAPDH)
becomes inactivated also by ROS thereby inhibiting glycolysis in favor of redirecting
glucose flux toward the PPP [135, 314, 315]. Oxidative stress alone increased glucose flux
to the PPP by nearly 60% in astrocytes exposed to H2O2 and was increased by more than
six-fold in reactive astrocytes via LPS stimulation [247, 316, 317].
In Chapter 3, E4 astrocytes display 13C fractional enrichment patterns that reflect a
rerouting of glycolytic flux into a cyclical pattern whereby substrates re-enter the PPP
which indicates an increased reliance on PPP activity. Given PPP is increased in reactive
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astrocytes and during ROS formation, our data showing greater glucose utilization in the
PPP of E4 astrocytes indicates that E4 may be under increased oxidative stress and have a
predisposition toward reactivity. Furthermore, the data shows E2 astrocytes had the lowest
fractional enrichment in PPP intermediates and the highest enrichment of G3P, which
indicates less PPP activity and increased GAPDH activity, and thus may reflect lower
overall oxidative stress. However, further studies are needed to confirm whether this
metabolic phenotype contributes to the protective nature of E2 or conversely, the
deleterious nature of E4.
A deficiency in glucose metabolism increases the reliance on mitochondria to
produce ATP, which inherently elevates oxidative stress through increased production of
ROS [135]. Although Chapter 3 findings show E4 astrocytes displayed increased TCA
cycle labeling, which might indicate an increased reliance on mitochondrial energy
production, the increased labeling in amino acids synthesized by TCA intermediates
suggests an alternative. Accumulation of

13

C in the TCA cycle of E4 astrocytes opposes

oxidative conditions whereby CO2, in this case 13CO2, is lost due to respiration. This may
produce an energy deficit in E4 astrocytes if ATP production via glycolysis is stunted due
to PPP activity for oxidative stress management that might compromise their ability to
sustain their own energetic demands as well as those of neurons. Further, such an energy
deficit would likely explain for the decreased neurotrophic support of E4 astrocytes given
the extensive metabolic coupling of astrocytes and neurons, which includes the astrocytedependent redox management of neurons [310].
The increased TCA cycle labeling in E4 astrocytes described in Chapter 3 indicates
less CO2 respiration—which is supported by direct evidence of decreased mitochondrial
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respiration reported in Chapter 4. Furthermore, evidence from separate studies suggested
E4 astrocytes had decreased mitochondrial function, measured as reduced NADPH
turnover, and E4 mice had lower mitochondrial respiration in cortical and hippocampal
regions relative to E3 [144, 145]. Altogether, these results suggest decreased ETC activity,
albeit ROS are generated by higher and not lower ETC activity, ROS are generated by
dysfunctional respiratory chain complexes which may be occurring in E4 astrocytes
considering the lack of CO2 expiration [318]. However, ROS generation can also occur in
the cytoplasm through NADPH oxidase that is activated by Ca2+ [135]. Dysfunctional Ca2+
signaling has a formidable role in initiating astrocyte reactivity through calcineurin and
while E4 has been connected to increased calcineurin activation in mice and pericytes, no
link has been established specifically in astrocytes [101, 319-321].
Additionally, oxidative stress can exhibit metabolic changes in astrocytes when DNA
damage incurs, which activates PARP-1 that readily consumes NAD+ and inhibits
glycolysis [135]. This also serves to redirect glucose flux into the PPP to further aid in the
antioxidant capacity via glutathione but more importantly provides the necessary building
blocks for de novo nucleotide biosynthesis needed to repair DNA damage. Findings from
Chapter 3 not only indicate E4 astrocytes redirect glucose flux toward PPP and increase
glutathione synthesis, but they also exhibit greater nucleotide biosynthesis.
The increased nucleotide biosynthesis observed in E4 astrocytes might also reflect
increased mRNA synthesis. With the increases in protein expression that are exhibited by
reactive astrocytes, nucleotide biosynthesis must be a metabolic process that is
preemptively necessary for the induction of reactive astrocytes to accommodate for the
increased transcription that occurs. If E4 astrocytes are reactive at baseline, nucleotide
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biosynthesis is a metabolic pathway expected to increase and similar to my findings of
increased adenine, guanine, and uridine phosphates (AXP, GXP, UXP, respectively), the
primary visual cortex of E4 mice showed increased uridine- and cytidine-monophosphate
while the entorhinal cortex showed increased guanosine-monophosphate [226].
Interestingly, NAD+ consumed during PARP-1 activation would drive the
conversion of pyruvate to lactate, which was observed in both E4 mice and astrocytes and
as a known metabolic feature of reactive astrocytes to increase lactate production [98]. In
addition to increased lactate production, metabolic alterations of reactive astrocytes have
been noted in the TCA cycle, purines, pyrimidines, lysine, and glycerophospholipids [322].
These metabolic alterations can occur as a result of activating mechanisms to mitigate
oxidative stress, which is known to increase with astrocyte reactivity [135, 318]. Based on
these inferences, the metabolic alterations among E4 astrocytes reported throughout my
findings in Chapters 3 and 4 could be attributed to a state of reactivity inherent to E4
astrocytes at baseline.

5.4

The immunometabolic response of E4 astrocytes
An astrocyte-mediated mechanism of synaptic and neuronal loss associated with AD

is predicated on glial inflammation. Based my findings, I conclude E4 astrocytes exhibit a
metabolic phenotype indicative of activated inflammatory processes. Part of the astrocyte
response to inflammatory stimuli is met with metabolic alterations to accommodate for the
increased oxidative stress assumed from the reactive state. Whether the metabolic profile
of E4 astrocytes is initially driven by oxidative stress or inflammatory processes is
unknown—nevertheless, it is important to further understand their inflammatory response.
While the scope of my project does not encompass the entirety of investigations necessary
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to properly characterize the inflammatory response of E4 astrocytes, it does offer valuable
insight which could lend aid in directing future studies.
Some studies have suggested a countereffect of E4 in relation to E2 or E3, which
depicts a strong pro-inflammatory state in microglia and conversely, a less proinflammatory state in astrocytes [89, 323]. Authors suggest E4 microglia exhibit a more
pro-inflammatory state whereas E4 astrocytes exhibit a less profound pro-inflammatory
response when compared to E2 or E3. However, primary glial cultures (consisting
primarily of astrocytes) from Sprague-Dawley rats that were exposed to exogenous E4
produced a greater inflammatory response measured via IL-1β compared to exogenous E3
[324]. These results suggest an inflammatory effect inherent to E4, that even when
administered exogenously to astrocytes in culture, the inflammatory response is
exacerbated. If the mere presence of E4 exhibits pro-inflammatory properties, then E4
astrocytes may be predisposed to reactivity regardless of whether inflammatory stimuli is
received.
The neuroinflammatory response propagates in CNS cell types via cytokine
signaling, and as such many cytokines are among the proteins most highly expressed after
inflammatory stimulation. Cxcl10 expression in the brain was increased in mice after
systemic LPS injection and showed the second-highest degree of change among more than
100 other proteins involved in cytokine signaling [325]. In Chapter 4, E3 astrocytes exhibit
a similar pattern where Cxcl10 is one of the top two genes that increases with inflammatory
stimulation—yet E4 astrocytes do not (Figure 4.6). It is known Cxcl10 expression
markedly increases with inflammation and the lack of apparent increase in inflammatory
stimulated E4 astrocytes might suggest a deficit specifically in Cxcl10 [325]. However, a
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deficiency in Cxcl10 would likely reflect a decrease in effector pathways, albeit the high
gene ontology enrichment scores for lymphocyte chemotaxis and cytokine-mediated
signaling among E4 stimulated versus control astrocytes (Figure 4.6C, right) suggests
Cxcl10 is functional in E4. An alternative explanation for the lack of change in Cxcl10
among E4 astrocytes is that Cxcl10 is already actively expressed under normal conditions.
Cxcl10 might be expressed in E4 astrocytes if they were already reactive. Furthermore, the
magnitude of enrichment of these effector pathways in the E4-specific comparison is nearly
two-fold that of the E4 versus E3 stimulated comparison (Figure 4.6D, right), which also
suggests Cxcl10 is active in non-stimulated E4 astrocytes and supports the notion where
E4 is reactive at baseline.
Finally, the inflammatory response in astrocytes acts in a positive feed-forward loop
where prior inflammatory activation contributes to a heightened response after
encountering additional stimuli [326]. E4 may act to intensify the inflammatory response
in astrocytes even in the presence of other cell types If E4 astrocytes are reactive at baseline
and responded to the pro-inflammatory cocktail as if it were an additional stimuli, it might
explain why cytokine-mediated signaling scored higher in the E4-specific comparison and
the E4 versus E3 stimulated comparison (Figure 4.6D, right) in relation to the E3-specific
comparison (Figure 4.6B, right).
In contrast, an in vivo study using human APOE mice treated with LPS showed
inflammatory gene expression in E3 mice was 25% greater than E4 after five hours;
however, 10 hours following LPS stimulation the differences in gene expression were
greater in E4 mice [327]. In comparison to my results in Chapter 4, given the time frame
after exposure to inflammatory mediators was less than five hours, E4 astrocytes might
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show more robust changes in gene expression with a longer duration. Alas, considering the
metabolic effects of neuroinflammation in astrocytes are not well-characterized, utilizing
a combined metabolomics and transcriptomics approach to classify the immunometabolic
response in E3 versus E4 astrocytes offers insight not previously offered by other studies
to date.

5.5

The search for a treatment of Alzheimer’s disease
As medicine developed throughout the 19th century and into the new millennium,

greater resolution of molecular mechanisms of disease through technological advances also
allowed for the design of pharmacological drugs with specific targets. This provided
tremendous success in terms of improving human life that fostered our relationship with
illness into a narrative whereby diseases could be treated by first identifying a single
mechanism giving rise to the disease then designing a drug to correct the malfunction.
While this system has generated many effective treatments and even some cures for
disease, it promoted a directive which is not suitable for all types of human diseases, AD
being a prime example.
The AD field has been long dominated by focusing on neuronal features of disease;
for more than two decades the primary directive for treatment targeted amyloid. Decades
later the amyloid cascade hypothesis as a sole cause of AD was revised primarily only to
adopt tau. Although it is clear amyloid and tau are critical features of the disease process,
it appears the development of AD is more systemic involving many cell types of the brain,
in addition to peripheral risk factors outside the CNS.
An environment where impaired glucose metabolism, oxidative stress, and
neuroinflammation occur together was noted as the most likely combination of features
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known to produce conditions which lead to neurodegenerative disease [135]. It has been
postulated that altered cerebral glucose metabolism can influence oxidative conditions [via
inflammation], promoting the progression and pathogenesis of AD in neurons through
metabolic and mitochondrial deficits [136]. Furthermore, evidence supports oxidative
damage as a critical mediator of synaptic dysfunction in AD, lipid droplet formation, DNA
damage, and decreased brain glucose metabolism, which strongly associates with the
regional distribution of AD pathology [136]. I posit astrocytes as an arbitrator of such
events, especially in the case of E4.
Importantly, elements of AD pathology do appear to be reversible, particularly
amyloid, tau, and neuroinflammation [328]. A combined therapeutic approach targeting
glucose metabolism and inflammation in astrocytes might delay the onset of disease if
implemented early enough or stall progression when adopted in prodromal cases. Perhaps
studies in animal models might also suggest it would also improve cognitive deficits if
implemented even after the onset of disease.

5.6

Future studies
Developing a therapeutic intervention for E4 carriers might require elucidation of the

biological mechanism by which E4 exerts its influence on AD risk. Although the exact
mechanism has eluded researchers for decades, further investigation of glucose metabolism
in E4 astrocytes may lead to the eventual discovery. Utilizing a [1,2-13C] glucose tracer in
vitro would determine the contributions specifically of the PPP in E4 astrocytes, offering
gainful insight into oxidative versus non-oxidative branches of the PPP. This specific
glucose tracer could determine if E4 is utilizing the PPP for energy production (oxidative),
which might be a compensatory mechanism for the decrease in oxidation via TCA cycle
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substrate. I hypothesize E4 astrocytes are undergoing more oxidation in the PPP as it
provides the NADPH necessary for biosynthesis processes and redox management via
glutathione recycling. Furthermore, increased oxidative utility of the PPP might
compensate for the lack of oxidation occurring in the TCA cycle of E4 astrocytes.
If E4 is undergoing less oxidation of TCA substrates, which is suggested by my work,
and is not compensating through oxidation of alternative energy substrates, then E4
astrocytes are facing a striking energy deficit. Specifically, utilizing stable isotope tracers
of fatty acids, glutamine, and ketone bodies would reveal any deficit in the ability to
metabolize non-glucose substrates. Furthermore, measuring metabolism after addition of
anti-inflammatory mediators or anti-oxidants as potential metabolic correctors would
answer the question of whether the metabolic alterations associated with E4 astrocytes are
driven by either inflammatory or oxidative stress and also determine their utility as a
potential metabolic corrector to subdue the immunometabolic response. If successful,
coupling this approach with a humanized APOE and AD mouse model then measuring the
extent of amyloid and tau pathology, synaptic dysfunction, and cognitive decline would
test the hypothesis that metabolic dysfunction due to inflammatory and/or oxidative stress
in astrocytes leads to progression of AD.

5.7

Conclusion
In summary, I have demonstrated APOE alters cerebral glucose metabolism and

shown specific effects in central carbon metabolism within astrocytes whereby glycolytic
flux is rerouted to increase activity of the PPP in E4. Finally, I have shown differences in
the immunometabolic response of astrocytes, of which an acute inflammatory challenge
induces more robust metabolic and transcriptional changes in E3 astrocytes relative to E4.
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I posit the lack of metabolic response in E4 is attributed to pre-existing inflammatory
activation and increased presence of oxidative stress. Although additional studies are
necessary to fully elucidate the mechanism by which E4 imparts a greater risk for AD, this
work contributes to the body of APOE literature and offers direction to support future
investigations into the growing field of immunometabolism, especially in glia as a
significant contributor in AD progression.
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APPENDICES
5.8

APPENDIX 1 – CHAPTER 2 GRAPHICAL ABSTRACT

5.9

APPENDIX 2 – CHAPTER 3 GRAPHICAL ABSTRACT

Glucose utilization in astrocytes expressing either human E2 (green arrows) or E4 (red
arrows) relative to E3. E2 astrocytes display increased flux through glycolysis, a more
oxidative TCA cycle, and decreased pentose phosphate pathway (PPP) flux. E4
astrocytes display increased glucose flux through PPP, in both re-entry into glycolysis
(gluconeogenesis), increased biosynthesis, and increased lactate synthesis, with a less
oxidative TCA cycle.

132

5.10 APPENDIX 3 – LIST OF ABBREVIATIONS FOR APOLIPOPROTEIN E
NOMENCLATURE
Human gene = APOE
Human allele = epsilon • isoform (ex. ε2)
Human protein = APOE
Mouse gene = Apoe
Mouse protein = apoE
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Mentor: Elmer M. Price, PhD
Topic: Subventricular Zone Neural Progenitor Cell Differentiation and Migration
PEER REVIEWED PUBLICATIONS
Erick D. Lewis, Holden C. Williams, Maria E.C. Bruno, Arnold J. Stromberg, Hiroshi
Saito, Lance A. Johnson, and Marlene E. Starr. Exploring the Obesity Paradox in a
Murine Model of Sepsis: Improved Survival Despite Increased Organ Injury in
Obese Mice. Shock, 3 September 2021.
Brandon C. Farmer, Holden C. Williams, et al. APOE4 lowers energy expenditure in
females and impairs glucose oxidation by increasing flux through aerobic glycolysis.
Molecular Neurodegeneration, 6 September 2021.
Williams HC, Piron MA, Nation GK, Walsh AE, Young LEA, Sun RC, Johnson LA.
Oral Gavage Delivery of Stable Isotope Tracer for In Vivo Metabolomics. Metabolites, 8
December 2020.
Williams HC, Farmer BC, Piron MA, Walsh AE, Bruntz RC, Gentry MS, Sun RC,
Johnson LA. APOE alters glucose flux through central carbon pathways in astrocytes.
Neurobiology of Disease, 11 January 2020.
Brandon JA, Farmer BC, Williams HC, Johnson LA. APOE and Alzheimer’s Disease:
Neuroimaging of metabolic and cerebrovascular dysfunction. Frontiers in Aging, 14 June
2018.
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RESEARCH PRESENTATIONS – Oral Presentations
“Apolipoprotein E4 Glucose Hypometabolism and Alzheimer’s Disease Risk”, Research
Blitz Presentation, Department of Physiology Research Retreat, Lexington KY, May 5,
2018.
“Resolving APOE Genotype Effects on Brain Metabolism via Tracer Metabolomics”,
Department of Physiology Seminar Series, University of Kentucky College of Medicine,
Lexington KY, April 24, 2019.
“APOE Genotype Effect on Cerebral Glucose Metabolism as a Mechanism for Alzheimer’s
Disease Risk”, Research Blitz Presentation, Department of Physiology Research Retreat,
Lexington KY, May 14, 2018.
“APOE Genotype and Brain Metabolism”, Department of Physiology Seminar Series,
University of Kentucky College of Medicine, Lexington KY, May 27, 2020.
“APOE Genotype Effect on Cerebral Glucose Metabolism as a Mechanism for Alzheimer’s
Disease Risk”, Research Blitz Presentation, Department of Physiology Research Retreat,
Lexington KY, October 20, 2020.
“Oral Gavage Delivery of Stable Isotope Tracer for In Vivo Metabolomics”, Mito Journal
Club, Department of Neuroscience, University of Kentucky, January 20, 2021.
RESEARCH PRESENTATIONS – Abstract Presentations
Williams HC, Piron MA, Johnson LA. “Using tracer metabolomics to investigate the
effects of APOE on cerebral glucose metabolism.” Neurodegenerative Diseases: Biology
& Therapeutics, Cold Spring Harbor Laboratory. December 2, 2020
Williams HC, Allenger EJ, Walsh AE, Johnson LA. “Investigating the effects of APOE
on cerebral glucose metabolism using stable isotope resolved metabolomics.” Markesbery
Symposium on Aging and Dementia, Sanders-Brown Center on Aging, University of
Kentucky, Lexington, KY. November 9, 2020.
Williams HC, Allenger EJ, Walsh AE, Johnson LA. “Using Stable Isotope Resolved
Metabolomics to Investigate APOE-mediated Effects on Cerebral Glucose Metabolism.”
Department of Physiology Research Retreat, University of Kentucky, Lexington, KY.
October 19, 2020.
Williams HC, Piron MA, Young LEA, Sun RC, Johnson LA. “Measuring APOE Genotype
Effects on Cerebral Metabolism using Stable Isotope Resolved Metabolomics.”
Markesberry Symposium on Aging and Dementia, University of Kentucky, Lexington,
KY. November 6, 2019.
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Williams HC, Piron MA, Brandon JA, Young LEA, Gentry MS, Sun RC, Johnson LA.
“Cerebral Metabolism and Alzheimer’s Disease Risk: Investigating the Role of APOE
using Stable Isotope Resolved Metabolomics.” Cancer and Metabolism Symposium,
University of Kentucky, Lexington, KY. July 24, 2019.
Williams HC, Piron MA, Brandon JA, Young LEA, Gentry MS, Sun RC, Johnson LA.
“Cerebral Metabolism and Alzheimer’s Disease Risk: Investigating the Role of APOE
using Stable Isotope Resolved Metabolomics.” Alzheimer’s Association International
Conference, Los Angeles, CA. July 14-18, 2019.
Williams HC, Piron MA, Brandon JA, Sun RC, Johnson LA. “Cerebral Metabolism and
Alzheimer’s Disease Risk: Investigating the Role of APOE Using Stable-Isotope Resolved
Metabolomics.” Michigan Alzheimer’s Disease Research Center, Beyond Amyloid
Symposium, Grand Rapids, MI. June 19, 2019.
Williams HC, Piron MA, Brandon JA, Sun RC, Johnson LA. “Metabolic Reprogramming
and Alzheimer’s Disease Risk: The Role of Apolipoprotein E4.” Department of Physiology
Research & Education Day, University of Kentucky, Lexington, KY. May 22, 2019.
Piron MA, Williams HC, Brandon JA, Sun RC, Johnson LA. “Apolipoprotein E4 Reduces
Isocitrate Dehydrogenase Activity and Alters TCA Cycle Flux in Astrocytes.” Chellgren
Center Showcase of Undergraduate Scholars. Lexington, KY. April 24, 2019.
Williams HC, Piron MA, Brandon JA, Sun RC, Johnson LA. “Metabolic Reprogramming
and Alzheimer’s Disease Risk: The Role of Apolipoprotein E4.” Centers for Clinical and
Translational Science Annual Conference/Bluegrass Society for Neuroscience Spring
Neuroscience Day, Lexington, KY. April 15, 2019.
Williams HC, Piron MA, Brandon JA, Sun RC, Johnson LA. “Metabolic Reprogramming
and Alzheimer’s Disease Risk: The Role of Apolipoprotein E4.” Centers for Clinical and
Translational Science Annual Conference/Bluegrass Society for Neuroscience Spring
Neuroscience Day, Lexington, KY. April 15, 2019.
Williams HC, Farmer BC, Carter DJ, Brandon JA, Johnson LA. “Glia-Neuron Metabolic
Interaction in Alzheimer’s Disease: The Role of Apolipoprotein E.” Conference on Glial
Biology in Medicine, Roanoke, VA, October 14, 2018.
Farmer BC, Nation G, Williams HC, Carter DJ, Khanal RB, Wilwerding A, Brandon JA,
Gentry M, Sun R, Johnson LA. Indirect Calorimetry as a Novel Method to Study APOE’s
Role in Cerebral Metabolism and Alzheimer’s Disease Risk. 144th Annual American
Neurological Association Meeting. Annals of Neurology. Volume 86, Suppl 24. St Louis,
MO. October 14, 2018.
Williams HC, Farmer BC, Carter DJ, Fields LW, Khanal R, Kluemper J, Brandon JA,
Johnson LA. Apolipoprotein E4 Decreases Glycolysis and Reduces Both Glucose Uptake
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and Lactate Secretion in Astrocytes. Neurobiology of Brain Disorders, Gordon Research
Conference, Barcelona, Spain, August 5, 2018.
Williams HC, Farmer BC, Carter DJ, Fields LW, Khanal R, Kluemper J, Brandon JA,
Johnson LA. Metabolic Reprogramming and Alzheimer's Disease Risk: The Role of
Apolipoprotein E4. National IDeA Symposium, Washington DC, June 24, 2018.
Williams HC, Farmer BC, Carter DJ, Brandon JA, Johnson LA. “Astrocytes Expressing
Apolipoprotein E4 Show Reduced Glucose Uptake, Glycolysis and Lactate Secretion.”
Department of Physiology Retreat, University of Kentucky, May 16, 2018.
Williams HC, Farmer BC, Carter DJ, Brandon JA, Johnson LA. “Apolipoprotein E4
Decreases Glycolysis and Reduces Glucose Uptake and Lactate Secretion in Astrocytes.”,
Kentucky Chapter of the American Physiological Society, Annual Conference, University
of Louisville, April 7, 2018.
Farmer BC, Kluemper J, Williams HC, Fields LW, Carter DJ, Brandon JA, Johnson LA.
“ApoE4 Promotes Lipid Droplet Formation in Astrocytes.” Kentucky Chapter of the
American Physiological Society, Annual Conference, Univ of Louisville, April 7, 2018.
Brandon JA, Williams HC, Fields LW, Johnson LA. “APOE, Obesity, & Cerebral
Metabolism.” COCVD COBRE Retreat, University of Kentucky, January 11, 2018.
Williams H. C., Price, E. M. “Bio-engineered Brain Implant Redirects Endogenous Neural
Progenitor Cell Migration: Implications for Parkinson’s Disease.” Marshall University
Joan C. Edwards College of Medicine Research Day, March 24, 2017.
Greynolds HF, Williams HC, and Price EM. “A New Approach for the Therapy of
Parkinson’s Disease and other Neurological Disorders.” Undergraduate Research Day at
the Capitol. February 24, 2017.
COMMUNITY SERVICE
Peer Reviewer, Journal of Alzheimer’s Disease, July 2020.
Presenter, Science Night, Stonewall Elementary School, Lexington KY November 2019.
Presenter, Biobananza, Department of Physiology, University of Kentucky, October
2019.
Organizer and Presenter, Neuroscience Day, Brookville Elementary School, Brookville
OH, April 2019.
Peer Reviewer, Neuroscience Letters, April 2019.
Presenter, Science Night, Mary Todd Elementary School, Lexington KY March 28,
2019.
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Program Director, Brain Demo, Walnut Hill Day School, Lexington KY March 19,
2019.
Event Leader, Enrichment Friday, Mill Creek Elementary School, Lexington KY
November 2, 2018.
Presenter, Biobananza, Department of Physiology, University of Kentucky, October
2018.
Volunteer, Taste of Science Festival, “Nature, Nurture, Neuron: What’s my risk of
getting Alzheimer’s, and what can I do about it?”, Head to Head – the Science of Aging
& the Brain, Bear & The Butcher, Lexington KY, March 28, 2018
Presenter, Science Night, Stonewall Elementary School, Lexington KY April 19, 2018.
Judge, Kentucky American Water—Fayette County Public Schools District Science Fair,
Bryan Station High School, Lexington KY February 3, 2018
Volunteer, Brain Expo, College of Science, Marshall University, February 2016.
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